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An unbiased microarray analysis of post-mortem tissue of individuals diagnosed 
with major depressive disorder (MDD) reported on the dysregulation of the 
fibroblast growth factor (FGF) family in cortical and limbic regions.  This was the 
first study to implicate this system of growth factors in mood disorders.  While 
FGF2 gene expression was consistently downregulated in a number of brain 
regions in MDD, FGF9 gene expression was consistently upregulated in MDD.  
While we have recently characterized the behavioral and molecular effects of the 
well-known FGF2 ligand in emotionality, the role of FGF9 in affective behavior 
had yet to be explored.  Initial studies that paralleled FGF2 administration 
provided important information about method of administration, dosing, and time-
sensitivity of testing.  While chronic FGF2 had antidepressant-like and anxiolytic 
effects in animal models of depression, chronic FGF9 increased depression-like 
behavior and was anxiogenic.  Chronic injections of FGF9 decreased expression 
of FGFR1 in the dentate gyrus in the hippocampus suggesting that FGF9 may 
alter the level of FGF2/FGFR1 signaling.  In addition to the role of exogenous 
FGF9 in altering affective behaviors, endogenous FGF9 expression was 
increased by chronic social stress.  These findings support the hypothesis that 
FGF9 mediates the long-term negative aspects of neurotrophic factor 




in mechanisms underlying MDD, we also investigated the basal expression of 
FGF family members in the hippocampus over time.  FGF2 and FGFR1 both 
displayed endogenous circadian gene expression in the hippocampus.  
Exogenous administration of FGF2 also altered circadian locomotor activity.  
These data support the hypothesis that dysregulation of fibroblast growth factor 
system gene expression may cause a disruption in circadian rhythms that 
underlie sleep/wake cycles.  This series of studies increased our understanding 
of the role of the FGF family in affective behavior and circadian activity.  
Additionally, these studies suggest that dysregulation of FGF system gene 
expression in MDD may be a potential mechanism for alteration of circadian 
rhythms in individuals with this disorder.  Taken together, these findings implicate 
FGF9 as a novel mediator of anxiety-like and depression-like behavior, 











There is increasing evidence that both genetic and environmental components 
contribute to psychiatric illness.  Data also suggests that circadian activity may 
be affected by both genetic and environmental factors.  As circadian 
dysregulation is often observed in patients diagnosed with mood disorders, it is 
possible that a common mediator affects mood, environmental interaction, and 
circadian activity.  However, further study of the mechanisms underlying the 
development of mood disorders and disruption of circadian activity is necessary. 
 
Severe forms of depression affect between 2-5% of the United States’ population 
and up to 20% of the population suffer from milder symptoms (Blazer 2000).  
Depression can be diagnosed as major depressive disorder (MDD) when a 
patient displays a number of symptomatic criteria for longer than a two-week 
period (2000).  These symptoms include insomnia or hypersomnia, loss or gain 
of weight, low energy and feelings of hopelessness.  This syndrome can be 
highly variable and there is no objective diagnostic test for MDD.  MDD is a 
highly heritable psychiatric disorder in which 40-50% of the risk associated with 




Identifying particular genes that confer vulnerability to depression is complicated 
by the fact that, like most complex diseases, many genes likely contribute to the 
development of MDD.  The remaining non-genetic risk is also poorly 
characterized with implications that early childhood trauma, emotional stress, 
random developmental processes, and even viral infection may contribute to the 
etiology of depression (Nestler, Barrot et al. 2002).  Further investigation of the 
interaction between genetic predisposition and environmental components are 
important to both the prevention of the onset of depressive symptoms and to the 
discovery of novel treatments for MDD. 
 
Traditional approaches to psychiatric drug discovery have yielded few new 
targets for treatment of MDD.  Since novel compounds are currently screened for 
efficacy with established receptors or known targets, new drugs are at best 
refinements of classic drugs discovered decades ago.  These antidepressant 
therapies act mainly on serotonin and norepinephrine systems (Lenox 2002). 
While newer types of antidepressants are better tolerated and have fewer side 
effects, only 50% of depressed patients respond to current treatments and even 
then only 35-40% of drug-responsive patients achieve full relief from depressive 
symptoms (Cassano and Fava 2004).   
 
With the advancement of large-scale gene expression profiling, we have the 
opportunity to approach target discovery for neuropsychiatric disorders using a 




makes it possible to examine the complex interplay of molecular and 
physiological pathways.  By looking at differential gene expression in brain tissue 
of patients diagnosed with MDD compared to their age-matched controls, we can 
develop a better understanding of the gene expression “signature” of MDD while 
identifying truly novel targets.  
 
 
Discovery of the role of the FGF system in mood disorders 
 
 
Our lab, as part of the Pritzker Neuropsychiatric Disorders Research Consortium, 
aims to discover the neurobiological and genetic underpinnings of psychiatric 
disorders using large-scale microarray gene expression analysis.   To this end, 
post-mortem brain tissue from individuals diagnosed with MDD and bipolar 
disorder (BPD) was analyzed for changes in gene expression and compared to 
tissue of control subjects.  This approach resulted in the identification of 
dysregulation of the fibroblast growth factor (FGF) family gene expression in a 
number of cortical and subcortical brain regions in MDD (Evans, Choudary et al. 
2004; Evans, Choudary et al. ; Turner, Akil et al. 2006; Akil, Evans et al. 2008).  
While other labs have shown that growth factors are important in antidepressant 
activity and emotionality (Duman and Monteggia 2006; Kalueff, Avgustinovich et 
al. 2006; Warner-Schmidt and Duman 2008), this was the first time the FGF 
family had been implicated for a role in mood disorders.  Since our original study, 




hypothesis that FGF gene dysregulation is involved in MDD (Sibille, Arango et al. 
2004; Tochigi, Iwamoto et al. 2008). 
 
While initial studies in our lab have focused on determining the role of the well-
studied FGF2 ligand in emotionality (Turner, Gula et al. 2008; Perez, Clinton et 
al. 2009), FGF9 also appeared to be an attractive target for small molecule 
inhibition since it was consistently upregulated in MDD.  Conversely, FGF2 and 
FGF receptors were downregulated in MDD.  Although little is known about the 
physiological role of FGF9; its known structure, expression, and functions are 
reviewed below.  We found that FGF2 had antidepressant-like activity and acted 
as an endogenous inhibitor of anxiety (Turner, Gula et al. 2008).  Since FGF9 
expression was increased while FGF2 was decreased in MDD, we hypothesized 
that FGF9 might mediate negative effects on emotionality. 
 
FGF dysregulation was identified in the prefrontal cortex, anterior cingulate, and 
hippocampus (Evans, Choudary et al. 2004; Evans, Choudary et al. 2004b; 
Gaughran, Payne et al. 2006).  The hippocampus has a well-defined role in 
learning and memory, and it is also an important regulatory component of the 
stress response and the hypothalamic-pituitary-adrenal (HPA) axis (Jacobson 
and Sapolsky 1991; Eichenbaum, Otto et al. 1992).  In humans, the 
hippocampus shows signs of atrophy as a result of elevated glucocorticoids and 
severe traumatic stress (Jacobson and Sapolsky 1991).  Human brain imaging 




shrinking in recurrent depressive illness, Cushing’s syndrome, post traumatic 
stress disorder (PTSD), schizophrenia, and aging (Starkman, Gebarski et al. 
1992; Bogerts, Lieberman et al. 1993; Golomb, Kluger et al. 1994; Bremner, 
Randall et al. 1995; Gurvits, Shenton et al. 1996; Sheline, Wang et al. 1996).   
 
In addition to these human findings, a number of animal studies also implicated 
the hippocampus and have led to the development of the neurotrophic 
hypothesis of depression and antidepressant action.  The neurotrophic 
hypothesis is a proposed model in which chronic stress decreases hippocampal 
growth factors and antidepressants increase them (Duman, Heninger et al. 1997; 
Duman 2004).  The alteration of growth factors may mediate the structural 
damage and reduced neurogenesis in the hippocampus after stress.  
Additionally, growth factors may mediate the neuroprotective effects of 
antidepressant treatments (Mallei, Shi et al. 2002; Bachis, Mallei et al. 2008)   
 
Circadian abnormalities are often observed in depressed patients (Germain and 
Kupfer 2008).  It is possible that growth factors may play additional roles in 
environmental response and maintenance of normal circadian rhythms.  
Dysregulation of growth factors may lead to disruption in circadian activity and 
subsequent changes in environmental responses and mood.  Alternatively, 





While growth factors may modulate the hippocampal environment in response to 
stress and antidepressants, they may also be mediators of circadian activity.  For 
example, BDNF and trkB gene expression showed variation in a 24-hour cycle 
and have been associated with wakefulness (Bova, Micheli et al. 1998; 
Berchtold, Oliff et al. 1999).  Chronic administration of BDNF can also alter 
circadian rhythms including locomotor activity (Naert, Ixart et al. 2006).  Alteration 
of environmental awareness or exploration activity due to circadian fluctuations in 
BDNF and trkB expression, may help to maintain circadian rhythms.  Growth 
factors may alter hippocampal plasticity and may allow for an increased response 
to environmental changes and adaptive learning.   
 
In order to examine mechanisms underlying growth factor modulation of 
circadian rhythms and growth factor dysregulation in depression, approximations 
of symptoms of MDD as well as effective treatments in laboratory animals are 
essential for the development of new therapeutics.  As new targets are identified 
through microarray studies, animal models are indispensable tools for studying 
the neuropathology that underlies a target’s role in depression. While despair-
based models have predictive validity for monoamine-based antidepressants 
they may not be sufficient to identify therapeutic effects on different targets 
(Berton and Nestler 2006).  However, recent modifications of existing paradigms 
and development of new tests will help to detect antidepressant actions of 
compounds acting on a broad range of neural and genetic targets (Cryan, 




While animal models cannot fully recapitulate the symptoms underlying the 
human disorder, they can provide us with useful information about the interaction 






Based on the studies mentioned above, I hypothesized that FGF9 will have 
negative effects on anxiety-like and depression-like behavior.  In addition, FGF 
system expression will show circadian variation in the hippocampus. 
 
 
The fibroblast growth factor family 
 
 
The fibroblast growth factor (FGF) family consists of 22 known ligands and five 
known receptors in humans.  There are six subfamilies of FGF based on 
differences in homology and phylogeny: FGF1 and FGF2; FGF3, FGF7, FGF10 
and FGF22; FGF4, FGF5, and FGF6; FGF8, FGF17, and FGF18; FGF9, FGF16, 
and FGF20; and FGF19, FGF21, and FGF23 (Itoh and Ornitz 2004).  FGF15 
cannot be identified in the human genome.  FGF11-14, also referred to as 
fibroblast homologous factors (FHFs), are debated members of the FGF family 
because they do not bind to FGFRs.  They share homology and structure with 
other FGF ligands, but instead the principal targets of FHFs are intracellular 




and receptors make up a large and complex family of signaling molecules that 
are involved in embryonic development, tissue homeostasis and, when 
inappropriately expressed, are known to cause morphogenetic disorders or 
cancer (Dailey, Ambrosetti et al. 2005).  
 
 
Fibroblast growth factors in the central nervous system 
 
 
Among the many members of the FGF family, only a subset has been identified 
in the brain. FGF1 and FGF2 are the prototypical ligands of the FGF family, also 
called acidic and basic FGF respectively, and most of the effects of FGF in the 
brain are attributed to these ligands. FGF1 is expressed predominantly in 
neurons (Wilcox and Unnerstall 1991) while FGF2 is expressed in both neurons 
and glia (Eckenstein, Kuzis et al. 1994; Gomez-Pinilla, Lee et al. 1994; 
Vaccarino, Schwartz et al. 1999).  FGFs play a critical role in CNS development 
via neurogenesis, axon growth, and differentiation (Molteni, Fumagalli et al. 
2001; Vaccarino, Ganat et al. 2001).  FGFs are also important to the 
development and maintenance of neurons (Mufson, Kroin et al. 1999; Perrone-
Capano, Da Pozzo et al. 2000) including fate determination (Anderson 1993), 
migration, and differentiation (Kalcheim 1996). 
 
Three of the FGF receptors expressed in the CNS have been implicated in CNS 
function. FGFR1 has widespread neuronal expression from early development 




abundantly expressed in all hippocampal subfields as well as the cortex 
(Gonzalez, Berry et al. 1995; Belluardo, Wu et al. 1997).  FGFR1 may play a role 
in cortical lamination and patterning in early development (Shin, Korada et al. 
2004). FGFR2 and FGFR3 are found primarily in glia (Asai, Wanaka et al. 1993; 
Yazaki, Hosoi et al. 1994; Miyake, Hattori et al. 1996) and are weakly expressed 
in astrocytes of the hippocampus (Weickert, Kittell et al. 2005). While FGFR2 is 
preferentially expressed in neurons in early development and is primarily found 
as the IIIb isoform, it is expressed mostly in glia in adulthood as the IIIc isoform.  
Evidence suggests that FGFR2 plays a presynaptic organizational role in early 
development then switches to a role in neuroprotection and repair in adulthood 
consistent with temporal splice variant expression patterns (Alzheimer and 
Werner 2002; Umemori, Linhoff et al. 2004). FGFR4 is only expressed during the 
early stages of development and, except in the lateral habenular nucleus, it is 
undetectable in the adult CNS (Fuhrmann, Kinkl et al. 1999). 
 
A number of FGF ligands have been identified and studied in the CNS. Since 
most of what is known about the FGF roles in the CNS is attributed to the FGF1 
and FGF2 ligands, information about the expression and function of the other 
FGF family ligands in the CNS is highly fragmented.  For example, FGF4 and 
FGF8 are important for the development of the midbrain-hindbrain boundary of 
the neural plate via interaction with sonic hedgehog (shh).  FGF4 and FGF8 also 
coordinate the induction of the serotonergic and dopaminergic system (Ye, 





FGF9 is also expressed in the CNS and is described in greater detail below.  
Additionally, another member of the FGF9 family, FGF20, is a neurotrophic factor 
for rat midbrain dopaminergic neurons (Ohmachi, Mikami et al. 2003).  
Exogenous treatment of FGF20 and FGF2 of monkey stem cells in vitro resulted 
in differentiation into dopaminergic neurons that, when transplanted, alleviated 
symptoms of a primate PD disease model (Takagi, Takahashi et al. 2005).  
Although FGF19 is expressed in the fetal brain (Nishimura, Utsunomiya et al. 
1999), it primarily activates FGFR4 (Xie, Holcomb et al. 1999) that is primarily 
expressed in the habenula (Fuhrmann, Kinkl et al. 1999).  Lastly, inhibition of 
FGF22 or its subfamily members, FGF7 and FGF10, inhibited presynaptic 
differentiation of mossy fibers contacting granular neurons (Umemori, Linhoff et 
al. 2004).  This fragmented knowledge of ligands implicates FGF in a number of 
roles in the CNS both in development and adulthood.   
 
 
Fibroblast growth factor-9 
 
 
FGF9 (glia-activating factor) was first purified as a heparin-binding, secreted 
glycoprotein from a cultured human glioma cell line, NMC-G1, and acts as a 
trophic factor for primary rat glial cells (Naruo, Seko et al. 1993; Matsumoto-
Yoshitomi, Seko et al. 1995).  Although FGF9 was originally isolated from glioma 




characterized in the human and rat brain (Tagashira, Ozaki et al. 1995; Todo, 
Kondo et al. 1998).   
 
FGF9 is strongly expressed in many regions of the brain including cerebellar 
nuclei, brain stem nuclei, and hypothalamic nuclei (Tagashira, Ozaki et al. 1995).  
FGF9 mRNA signal is moderately strong in the rat hippocampus and cerebral 
cortex (Tagashira, Ozaki et al. 1995) with very strong expression in the human 
hippocampus (Todo, Kondo et al. 1998).  FGF9 mRNA is also intensely 
expressed in human and rat spinal motor neurons (Nakamura, Todo et al. 1997). 
Furthermore, weak glial FGF9 expression is characterized (Nakamura, Todo et 
al. 1999) and showed marked upregulation in pathological conditions such as 
Alzheimer’s disease and amyotrophic lateral sclerosis (Nakamura, Arima et al. 
1998).  To this end the therapeutic use of an FGF9 antagonist has been 
suggested for a number of neurodegenerative diseases (Kanda, Iwasaki et al. 
1999; Pataky, Borisoff et al. 2000).   
 
 
Structural characteristics of fibroblast growth factor-9 
 
 
All FGFs share a homologous core region of 120-130 amino acids ordered into 
twelve antiparallel β-strands (β1-β12) flanked by an amino and a carboxyl termini. 
Crystal structures of FGF1, FGF2, and FGF7 reveal that the common core 
structure consists of three copies of a four-stranded β-sheet known as the β-




in the N- and C- terminal tails accounts for much of the variation in biological 
activity of the ligands (Mohammadi, Olsen et al. 2005).  The β1-β2 loop and parts 
of β10 and β12 make up the binding site for heparan sulphate glycosaminoglycan 
(HSGAG).  HSGAG aids in the ligand-receptor binding of FGF-FGFR by binding 
to both FGF and FGFR simultaneously and stabilizing the protein-protein 
interaction.  HSGAGs also stabilizes FGF against degradation, acts as a storage 
reservoir for ligand and determines the radius of FGF diffusion (Beenken and 
Mohammadi 2009). 
 
The crystal structure of FGF9 reveals, like other FGFs, a common core of N- and 
C-terminal segments outside the beta-trefoil core (Figure 1-1).  The N- and C-
terminal segments differ in length with unknown functional relevance.  FGF1, 
FGF2, and FGF4 have short C-terminal segments while FGF3, FGF5, and FGF8 
have long terminal segments (Plotnikov, Eliseenkova et al. 2001).  FGF9 
uniquely and readily forms dimers under physiological conditions  
(Kd = 680nM) (Plotnikov, Eliseenkova et al. 2001).  Most of the residues involved 
in the formation of the FGF9 dimer are also those that correspond to the major 
receptor-binding site in FGF2 (Venkataraman, Raman et al. 1999).  Therefore 
dimer formation may be an autoinhibitory mechanism of FGF9 action; 
disassociation must occur for the molecule to be accessible to the receptor. 
FGF9 dimer interface analysis shows interactions between the N- and C-terminal 
segments that are described as the driving force behind dimer formation.  In 




the N-terminal of FGF9 forms a highly organized α-helix (αN).  The FGF9 N-
terminal is composed of 17 residues compared to four residues in FGF1 and 
three residues in FGF2 (Plotnikov, Eliseenkova et al. 2001). The FGF9 dimer 
mainly consists of hydrophobic contacts but has four hydrogen bonds and two 
salt bridges in the interaction of the C-terminals of the FGF9 monomers (Hecht, 
Adar et al. 2001).   
 
FGF9 is a unique member of the FGF family in that it lacks a typical secretory 
signaling peptide, yet it is still efficiently secreted via a non-cleaved sequence 
consisting of its first 33 residues (Matsumoto-Yoshitomi, Habashita et al. 1997; 
Revest, DeMoerlooze et al. 2000). The major difference between the FGF9 
structure and those of prototypical FGFs, FGF1 and FGF2, is the β1-β2 and β9-
β10 loop conformations. The β1-β2 loop corresponds to a high affinity receptor-
binding region consisting of several disjoint tight binding residues.  The β1-β2 
loop is one residue shorter in FGF9. The β9-β10 loop corresponds to a “low-
affinity binding loop” (LAL) that is longer in FGF9 by 4-6 residues than its 
corresponding loop in FGF1 or FGF2 (Figure 1-2) (Plotnikov, Eliseenkova et al. 
2001).  The steric bulk of the LAL of FGF9 may affect its interaction with 
receptors as compared to its counterparts with smaller LAL.  FGF12 is the only 
other FGF ligand with a similar LAL (Taylor 2007).  These differences may play a 
role in the affinity for FGF9 to HSGAGs that are necessary for receptor 
interaction. The structural differences between FGF9 and prototypical FGFs also 




Receptor binding specificity of fibroblast growth factor-9 
 
 
The five FGF receptors (FGFRs) are a family of tyrosine kinase receptors that 
consist of three extracellular immunoglobulin domains (D1-D3), a single-pass 
transmembrane domain and a cytoplasmic tyrosine kinase domain (Mohammadi, 
Olsen et al. 2005). Alternative splicing, occurring in FGFR1-3 on the C-terminal 
of the D3 domain, creates initially exclusive isoforms of the receptor (FGFR1-IIIb 
and FGFR1-IIIc) that have distinct binding specificities (Johnson, Lu et al. 1991). 
It is known that receptor splice variants provide some of the ligand-binding 
specificity of FGFs (Ornitz, Xu et al. 1996).  
 
The activation model of FGF signaling begins with FGF binding to HSGAGs, 
followed by receptor dimerization, autophosporylation and downstream signaling 
(Ornitz, Yayon et al. 1992; Vainikka, Partanen et al. 1992; Ornitz, Herr et al. 
1995).  FGF interaction with HSGAGs is well-documented and allows for the 
formation of distinct complexes that bind with low affinity (Kd= 2X10-9) but with 
large capacity (106 sites/cell) (Yayon, Klagsbrun et al. 1991; Spivak-Kroizman, 
Lemmon et al. 1994). The crystal structure of a ternary FGF2-FGFR1-heparin 
complex provides a model by which heparin aids the induction of FGF receptor 
dimerization (Schlessinger 2000).  HSGAGs interact with the HSGAG binding 
sites of FGF and promote the formation of a 1:1:1 FGF2-FGFR1-heparin 
complex.  Another ternary complex is recruited to the first complex via weak 
interactions of the first ternary complex with the FGF receptor of the recruited 




different sulfation patterns or length may play a role in altering both binding 
affinities and specific biological activity.   
 
The crystal structure for FGF9 binding to any receptor with HSGAGs has not 
been determined.  However, modeling of the FGF9-FGFR1 interaction by 
superimposing FGF9 into the FGF2-FGFR1-heparin complex reveals a positively 
charged groove in heparin binding sites similar to FGF2, but highlights multiple 
alternative sites for heparin interaction that may affect biological activity 
(Plotnikov, Hubbard et al. 2000).  FGF9 binds preferentially to FGFR2c and 
FGFR3c receptors (Hecht, Zimmerman et al. 1995; Santos-Ocampo, Colvin et al. 
1996; Chellaiah, Yuan et al. 1999).  The FGF9 structural differences within the β-
trefoil sheet and at the N-terminal sterically hinder FGF9 from engaging with 
FGFR1c (Plotnikov, Eliseenkova et al. 2001).  
 
 
Fibroblast growth factor-9 signaling 
 
 
The five FGF receptors are known to act through two main intracellular 
pathways, the phospholipase C (PLC) γ1 (also known as FRS1) pathway and the 
FGFR substrate 2 (FRS2) pathway. The PLCγ pathway activates downstream 
PKC leading to changes in cytoskeletal organization. The PLCγ pathway also 
activates the PDK/AKT survival (anti-apoptotic) pathway. The FRS2 pathway 
activates the Ras/RAF/MAPK (ERKs,P38,JNKs) cascade that leads to 




Chimeric receptor studies using the cytoplasmic domains of FGFR1, FGFR3 and 
FGFR4 in vitro show that differences in ligand binding do not activate different 
downstream proteins.  Instead the magnitude of the tyrosine kinase activity is the 
main difference in receptor activation (Raffioni, Thomas et al. 1999).  Therefore it 
is hypothesized that FGFR subtypes drive the same signaling cascades but with 
different strengths.  The mechanisms underlying the diverse and sometimes 
paradoxical signaling of the FGF family has been reviewed in Dailey, Ambrosetti 
et al (2005).  They concluded that the signaling response is multifaceted and 
complex.  The specific biological response that a cell will deliver will depend on 
the interplay between the presence or absence of specific FGFs, feedback loops, 
and crosstalk with other signaling networks.  The response will also depend on 
the availability of the “target” genes to be activated or suppressed in a given cell 
type. The diversity of the FGF ligands and receptors may be necessary for the 
activation of varied target cell types and complicated feedback systems. 
 
 
Transgenic fibroblast growth factor-9 mouse models 
 
 
While no studies have specifically analyzed the effect of FGF9 knockouts on 
behavior, the following work summarizes the transgenic studies to date.  FGF9 
knockout mice exhibited male-to-female sex reversal (Colvin, Green et al. 2001) 
and died at birth due to lung hypoplasia (Colvin, White et al. 2001).  In order to 
characterize the role of FGF9 in prostate development and tissue homeostatis, 




and reverted to a true conditional knockout after recombination induced by Cre 
recombinase (Lin, Liu et al. 2006).  However, no studies besides the 
characterization of a viable inducible knockout have been published.  FGF9 
tissue-specific transgenic overexpressers have been developed for skeletal and 
lung development studies. Increased FGF9 expression in cranial mesenchyme 
cells led to developmental skull abnormalities and cataracts (Govindarajan and 
Overbeek 2006).  Overexpression of FGF9 in developing lung epithelium resulted 
in hyperplasia and decreased epithelial branching (White, Xu et al. 2006).   
 
 
Fibroblast growth factor system and affective behavior 
 
 
While little is known about the role of FGF9 in affective behavior, our lab has 
recently characterized the effects of FGF2 in both anxiety-like and depression-
like behavior (Turner, Gula et al. 2008; Perez, Clinton et al. 2009).  Since FGF2 
is one of the better-known family members of the FGF family, the FGF2 link to 
the neurotrophic hypothesis and its role in mood disorders is more apparent 
(Newton and Duman 2004; Berton and Nestler 2006; Turner, Calvo et al. 2008).   
 
FGF2 plays a critical role in the development of the brain structure and promotes 
the proliferation and survival of fetal and postnatal cells cultured from many brain 
regions (Ray, Peterson et al. 1993) including the hippocampus (Walicke, Cowan 
et al. 1986; Ray, Peterson et al. 1993).  A single subcutaneous injection of FGF2, 




resulted in a larger hippocampal volume into adulthood (Cheng, Black et al. 
2002).  Conversely, FGF1 receptor knockouts had decreased hippocampal cell 
proliferation resulting in permanent atrophy (Ohkubo, Uchida et al. 2004).   
 
FGF2 is also important in the adult brain as evidenced by its role in adult 
neurogenesis.  Intracerebroventricular infusions of FGF2 increased neurogenesis 
in the subventricular zone of adult rats (Wagner, Black et al. 1999).   
Furthermore, chronic posterior lateral ventricular injections FGF2 in middle-aged 
rats increased neurogenesis and enhanced dendritic growth in the subventricular 
zone and dentate gyrus (Rai, Hattiangady et al. 2007).  In support of the 
hypothesis that FGF2 mediates the effects of antidepressants and subsequent 
increased neurogenesis following antidepressant treatment, FGF2 expression is 
increased following antidepressant treatment (Mallei, Shi et al. 2002; Bachis, 
Mallei et al. 2008). 
 
Our lab has also shown that gene expression of FGF2 and its primary receptor, 
FGFR1, are decreased by acute social defeat in all sub-regions of the adult rat 
hippocampus (Turner, Calvo et al. 2008).  Our lab has also shown that acute 
peripheral administration of FGF2 increased anxiety-like behavior (Perez, 2009) 
and chronic peripheral administration reversed this effect resulting in an 
anxiolytic response (Perez, Clinton et al. 2009).  Furthermore, our lab has shown 
that basal FGF2 expression is altered in the hippocampus of rats selectively bred 




al. 2006).  Specifically FGF2 gene expression is decreased in low-response to 
novelty/high-anxiety (LR) rats compared to high-response to novelty/low-anxiety 
(HR) rats.  This data suggests that differences in FGF system expression may 
change the way that animals interact with their environment.  These changes 
might be directly related to alterations of mood (chapter 3) and might also 
underlie changes observed in circadian rhythms following FGF2 microinjection 
(chapter 4). 
 
In our studies of the role of FGF2 in depression-like behavior, we characterized 
both the effects of FGF2 and the FG loop (FGL) of the neural cell adhesion 
molecule (NCAM) (Turner, Gula et al. 2008).  FGF2 primarily activates FGFR1 
but can also bind and activate all four FGF receptors (Reuss and von Bohlen und 
Halbach 2003). The FGL is the F and G β-strands and the interconnecting loop 
region of NCAM’s second fibronectin type 3 module, and both NCAM (Williams, 
Furness et al. 1994; Kiselyov, Skladchikova et al. 2003; Christensen, Lauridsen 
et al. 2006) and FGL (Kiselyov, Soroka et al. 2005) activate FGF receptors.  
Acute microinjections of both FGF2 and FGL decreased depression-like behavior 
as evidenced by a decrease in percent time spent immobile on the forced swim 
test (FST) (Turner, Gula et al. 2008).    
 
Chronic microinjection of FGF2 also produced antidepressant-like effects in the 
FST and latency to feed as measured in novelty-suppressed feeding test (NST).  




microinjection also caused a dentate-gyrus specific increase in FGFR1 gene 
expression 24 hours after FGF2 injection although it did not alter endogenous 
gene expression of FGF2 (Turner, Gula et al. 2008).  While we could not explain 
the regulation of receptor mRNA, we identified that is possible to observe 
immediate changes in FGF family regulation.   
 
 
Circadian rhythm disturbances in depression 
 
 
Most organisms show a wide range of cyclical activities over a 24-hour period, 
that we refer to as circadian activity.  Circadian activity includes changes in core 
body temperature, secretion of hormones such as cortisol, and maintenance of 
the sleep-wake cycle. In humans the sleep-wake cycle is the most obvious daily 
rhythm (Germain and Kupfer 2008).  The superchiasmatic nucleus (SCN) of the 
hypothalamus is the central pacemaker or the masterclock and can maintain 
rhythmic activity in the absence of input from any other part of the brain (Inouye 
and Kawamura 1979).  The major output of the SCN is to the paraventricular 
nucleus (PVN) of the hypothalamus and via a multisynaptic pathway to the pineal 
gland, where melatonin is synthesized.  Melatonin is a human biochemical 
transducer of the photoperiod to all cells in the body, and it is secreted at night 
and suppressed during the day (Simonneaux and Ribelayga 2003).  The PVN is 
also the site of cortcotrophin releasing factor (CRF) – secreting neurons, which 





Regulation of the sleep-wake cycle is complex and involves numerous brain 
areas and pathways (Saper, Scammell et al. 2005). Cortical arousal is mediated 
by cholinergic and aminergic activity from the pontine tegmentum, locus 
coereleus, and raphe nuclei. Activity of these wakefulness systems is modulated 
by orexin, a neuropeptide produced by the lateral hypothalamus (Sakurai, 
Amemiya et al. 1998; Chemelli, Willie et al. 1999).  The endogenous timekeeping 
system allows for the anticipation and preparation for environmental changes 
associated with day and night.  Most human functions, both physical and mental, 
display circadian rhythmicity, therefore it is intuitive that disruption of these 
activities can lead to both physical and mental pathological symptoms. 
 
In healthy human subjects, mood variation over a 24-hour cycle depends on the 
interaction between the circadian phase and prior wakefulness (Boivin, Czeisler 
et al. 1997).  Not surprisingly, there is a strong association between depression 
and sleep dysregulation in humans (Wirz-Justice 2006).  As many as 90% of 
depressed patients report impairment of sleep quality (Casper, Redmond et al. 
1985)  and alterations in sleep architecture were also observed objectively 
(Kupfer and Foster 1972).  Sleep architecture abnormalities consisted of a 
decreased slow-wave sleep and increased rapid eye moment (REM) in 
depressed patients.  However, it is still not known if changes in sleep quality or 
quantity lead to neurobiological dysfunction and subsequently a depressed state. 
Alternatively, alterations of the sleep-wake cycle could be secondary to the onset 




While the sleep-wake cycle is the most obvious circadian rhythm in humans, 
additional circadian activity disruption has been reported in MDD.  Normally, core 
body temperature peaks in the evening and is at a nadir in the last third of the 
night.  However, elevated nocturnal body temperature is reported in individuals 
with MDD (Souetre, Salvati et al. 1988; Harding and Duncan 1996) and is 
normalized with clinical improvement (Avery, Wildschiodtz et al. 1982; Avery, 
Wildschiodtz et al. 1982).  In addition to differences in core body temperature, 
abnormalities in cortisol secretion rhythms have been revealed in MDD.  In 
normal subjects, cortisol secretion peaks in the morning and progressively 
declines to a nadir in the evening.  In depressed subjects there is an overall 
increase in cortisol secretion that may disrupt HPA axis function, and the largest 
increase in cortisol secretion compared to controls is seen at the nadir of the 
circadian rhythm.  There is also an earlier onset of first cortisol secretory episode 
in depressed subjects (Van Cauter, Leproult et al. 1996). 
 
One chronobiological model, formulated to explain sleep-wake disturbance in 
MDD, hypothesized that the amount of SWS at night is determined by prior 
wakefulness (Borbely 1982).  The level of sleep propensity during the day and 
the depth of sleep at night contribute to the “S” process.  “S” accumulates during 
waking hours as the propensity for SWS increases.  “S” dissipates at night 
leading to a decline in SWS.  A second process, “C”, is the represents circadian 
control of sleep propensity, highest at 0300-0500 h and lowest a 1600 h in 




When “S” is equal to “C,” an individual wakes up.  It was proposed that the 
reduction in SWS is the result of impairment in the “S” process where individuals 
with MDD have decreased accumulation of sleep pressure and reduced 
dissipation of SWS at night (Borbely 1982).  The impairment of “S” during the day 
can lead to frequent sleep disturbance and early wakening.   
 
In support of this hypothesis, one night sleep deprivation of patients with MDD 
has a dramatic antidepressant effect.  Unfortunately this effect is transient and 
short-lasting (Wirz-Justice and Van den Hoofdakker 1999).  A similar 
antidepressant effect was observed in rodent models of sleep deprivation in 
which 24 hours of sleep deprivation increased the swimming activity of rats in the 
forced swim test (FST) (Lopez-Rodriguez, Kim et al. 2004).  This 
chronobiological model still does not establish the causality of circadian 
disruption and depression symptoms, but sleep deprivation studies show that 
mood can be briefly improved by sleep deprivation and correction of the sleep-
wake cycle.  As the human antidepressant effect is transient, it is possibie that 
patients with MDD have an inherent circadian dysregulation of the sleep-wake 
cycle. 
 
Recent studies show that there is a diurnal rhythm to dendritic architecture and 
spine density in pyramidal neurons in the rat infralimbic cortex (Perez-Cruz, 
Simon et al. 2009).  Since growth factors have gene expression variation in the 




Dolci, Montaruli et al. 2003), it is possible that growth factors modulate synaptic 
plasticity through dendritic architecture and spine formation during a 24-hour 
cycle.  The modulation of synaptic plasticity may underlie response and reactivity 
to environment that are important components of behavioral activity.  Given that 
chronic microinjection of BDNF interrupted normal circadian activity patterns 
(Naert, Ixart et al. 2006), it is also possible that alterations of other growth factors’ 
basal expression rhythms may disturb circadian activity patterns.   Since we have 
implicated the FGF family in mood disorders, it is reasonable to ask whether FGF 
gene expression is regulated over a 24-hour period and if this pattern is altered in 
MDD.  It is possible that the FGF system is responsible for changes in structural 
plasticity that link stress-induced effects with disrupted biological rhythms 
involved in the regulation of mood. 
 
In healthy subjects, mood variations across the day are dependent on 
interactions between circadian phase and duration of prior wakefulness (Boivin, 
Czeisler et al. 1997).  Considering there is such a strong correlation between 
sleep and mood, it is not surprising that depressed patients, who often complain 
of sleep disturbances, are profoundly affected by alterations of circadian rhythm.   
Depressed patients showed sustained activity in brainstem and hypothalamic 
regions involved in wakefulness compared to healthy subjects (Buysse, 
Nofzinger et al. 2004).  While the neural mechanisms that underlie the cause of 
these disruptions have not been elucidated, factors that modulate circadian 




Role of the hippocampus in depression and stress response 
 
 
The hippocampus is a key modulator of hypothalamic-pituitary-adrenal (HPA) 
axis activation.  The HPA axis is a prominent mechanism by which the brain 
reacts to acute and chronic stress.  Neurons in the paraventricular nucleus (PVN) 
of the hypothalamus secrete corticotropin releasing factor (CRF) that stimulates 
the synthesis and release of glucocorticoids from the adrenal cortex. 
Glucocorticoids, cortisol in humans and corticosterone in rats, are well 
characterized in the pathophysiology of depression (Ursin and Olff 1993).  
 
The hippocampus inhibits the hypothalamic CRF-containing neurons via a 
polysynaptic circuit. A number of studies highlight the link between depression 
and HPA axis dysregulation (Feder, Coplan et al. 2004; Wichniak, Brunner et al. 
2004; Duval, Mokrani et al. 2006).  Most of these studies focus on basal activity 
of the HPA axis in depressed individuals (Halbreich, Asnis et al. 1985; Lemus, 
Asnis et al. 1987; Posener, Charles et al. 2004).  Fifty to 60% of depressed 
patients exhibit increased levels of cortisol and loss of feedback inhibition of the 
HPA axis (Holsboer, Von Bardeleben et al. 1984; Gold, Calabrese et al. 1986).   
 
In addition to modulating the stress reponse, the hippocampus is one the primary 
sites of adult neurogenesis. The connection between mood disorders and 
neurogenesis is still being elucidated.  It is thought that stress-induced decreases 
in neurogenesis may be an important factor in eliciting depressive episodes 




2003).  Animal models of stress show decreased cell survival and disruption of 
cell proliferation while antidepressants reverse these effects (Czeh, Welt et al. 
2002; Malberg and Duman 2003).   
 
While studies have shown that the behavioral effects of antidepressants are 
dependent on neurogenesis (Santarelli, Saxe et al. 2003), others have shown 
that neurogenesis effects depression-like activity in only some behavioral 
measures (David, Samuels et al. 2009).  Also, decreased hippocampal volume 
has been observed in depressed individuals (Sheline 1996; Sheline, Wang et al. 
1996; Sheline, Sanghavi et al. 1999) and may be attributed to a decrease in 
hippocampal neurogenesis (Gould, Tanapat et al. 1998).  While the debate still 
continues on the role of neurogenesis in depression, the functions of the 
hippocampus in stress and depression may become increasingly important to the 
treatment of MDD. 
 
Changes in other growth factors in the hippocampus have also been associated 
with both mood disorders (Duman 2004) and neurogenesis.  Previous work has 
shown that brain-derived neurotrophic factor (BDNF) and vascular endothelial 
growth factor (VEGF) are responsible for modulating structural plasticity changes 
resulting from antidepressant treatment. These changes in plasticity have been 
attributed to neurogenesis in the hippocampus (Shirayama, Chen et al. 2002; 
Schmidt and Duman 2007; Warner-Schmidt and Duman 2007).  Furthermore, 




an antidepressant-like behavioral effect in rats (Shirayama, Chen et al. 2002). 
Conversely, transgenic mice with reduced BDNF signaling are insensitive to 
antidepressants in behavioral tests (Sairanen, Lucas et al. 2005).   
 
These findings and recent findings from our lab support the neurotrophic 
hypothesis that growth factors play an essential role in hippocampal structural 
plasticity and subsequent behavioral consequences.  It is possible that 
alterations in FGF family expression observed in the hippocampus of individuals 
diagnosed with MDD underlie the pathophysiology of the disorder.  Further 
research into the underlying mechanism of FGF action on hippocampal function 
will be necessary to validate this hypothesis. 
 
 
Animal models for the assessment of novel antidepressant targets 
 
 
Animal models of depression are essential tools utilized to reproduce human 
symptoms of MDD to better understand the disorder’s underlying 
pathophysiology. Given the variability and complexity of symptoms displayed by 
humans with MDD, it is difficult to demonstrate equivalence between animal 
behavior and human depression. However, there are a number of established 
behavioral models that mimic MDD symptoms, cause depression-like and 
anxiety-like behavioral changes, and respond to antidepressant treatment.  




condition, a number of environmental triggers and behavioral endpoints have had 
predictive value for determining therapeutic antidepressant effects in humans.  
As the search for novel antidepressants continues, there is concern whether 
models that have been traditionally used to determine the efficacy of classic 
antidepressants, tricyclics and monoamine-based therapies, can be used for 
discovery of new antidepressant compounds.  These predictive models are 
useful for high-throughput screening of target compounds.  However, a number 
of modifications to older models and newer models have emerged that have face 
validity producing animal behaviors with likeness to human symptoms (Petit-
Demouliere, Chenu et al. 2005).  These modified and newer animal models allow 
for validation of antidepressant efficacy outside of tasks that were specifically 
developed for monoaminergic action.  Although the link between stress and 
depression is not completely understood, human depression is often triggered by 
traumatic life events in both childhood and adulthood and can be exacerbated by 
a number of physical and social stressors.  Due to their aeteological validity, a 
number of tests make use of acute or chronic stress to produce a depression-like 
effect in rats.   
 
The forced swim test (FST) was originally designed as a primary screen for the 
effect of acute antidepressants (Porsolt, Bertin et al. 1977) and its validity is 
based primarily on observations seen with the administration of monoamine 
oxidase inhibitors (MAO-Is) and tricyclic drugs (TCAs).  However, additional 




as a neuropharmacological tool.  Recent studies have utilized the FST for more 
than just screening of monaminergic activity. The uncontrollable stress involved 
in the test has led to the use of the FST as a model of depression.  Data supports 
that acute antidepressant treatment attenuates swim-stress induced 
corticosterone release in the rat (Baez and Volosin 1994).  Also, the fact that 
electroconvulsive seizures are effective in the test speaks to its ability to pick up 
broader mechanisms of action (Nestler, Gould et al. 2002).  
 
The FST has been used to validate the effect of neurotrophic factors on 
depression-like behavior.  Brain-derived neurotrophic factor (BDNF) infusion into 
the midbrain decreased immobility time 70% compared to vehicle controls.  
Additionally, infusion of BDNF into the ventral tegmental area (VTA) resulted in a 
57% shorter latency to immobility compared to vehicle controls (Eisch, Bolanos 
et al. 2003).  Direct injection of BDNF into the VTA has a pro-depressant effect 
on the FST while BDNF infusion into the midbrain and hippocampus cause an 
antidepressant-like effect in the FST. A modified FST, consisting of multiple swim 
tests following the initial 15-minute Day One swim, showed that central 
administration of either BDNF or IGF-1 caused a persistent antidepressant-like 
effect in the forced swim test lasting at least six days (Hoshaw, Malberg et al. 
2005). In our lab, chronic microinjection of FGF2 into the left lateral ventricle 
resulted in a significant decrease in percent time spent immobile and an increase 
in percent time spent swimming (Turner, Gula et al. 2008).  While the construct 




acute and non-ecologically relevant stressor, its predictive value and reliability 
are still extremely high (Petit-Demouliere, Chenu et al. 2005).   
 
Novelty-supressed feeding (NSF) and novelty-induced hypophagia (NIH) are 
behavioral paradigms that involve food deprivation and placement of a rat into a 
novel environment with food.  This test is sensitive to chronic antidepressant 
administration but not to acute administration (Bodnoff, Suranyi-Cadotte et al. 
1988; Merali, Brennan et al. 2003; Santarelli, Saxe et al. 2003).  Latency to 
consume a food pellet is used as a measure for anxiety-like behavior.  The major 
problem with NSF is that it is also affected by acute administration of an 
anxiolytic (Duman and Monteggia 2006), and it is not specific to antidepressants. 
Although, this test does not test directly for depression-like behavior, high 
comorbidity rates between depression and anxiety are observed in human 
patients (Gorman 1996).  Of particular importance, it is difficult to see depressant 
or anxiogenic effects in the NSF since latency to feed in normal rats is generally 
the full time allotted. Due to this ceiling effect, the NSF test is not a good tool for 
assessing antidepressant targets that may have anxiogenic or depressionogenic 
effects. 
 
To address the shortcomings of the NSF model, a modified version of NSF, the 
NIH model, was developed.  In the NIH model, mice are trained to drink liquid 
containing sweetened condensed milk.  Following the training period, the animals 




a novel environment.   This model avoids the fixed-food deprivation necessary for 
NSF and subsequent interference of appetite.  Chronic, but not subchronic, 
antidepressant treatment reduces latency to drink in the novel environment 
(Dulawa and Hen 2005).  This NIH model has mainly been used for mice, but it is 
very similar to the rat sucrose preference test which measures percent sucrose 
consumed compared to tap water to assess anhedonia.  Preference deficits for 
the sucrose test exist after two weeks of chronic mild stress and can be reversed 
by chronic but not subchronic antidepressant treatment (Willner, Towell et al. 
1987).  A modified version of the NIH model involving sucrose preference may be 
suitable for assessing anhedonia in rats.  Normal unstressed rats will drink high 
percentages of sucrose solutions therefore providing for room to see an 
anhedonic effect of antidepressant targets. 
 
The chronic social stress paradigm is a model of social subordination in which an 
adult male rat (intruder) is introduced into the cage of an unfamiliar, aggressor rat 
(resident).  The intruder is removed as soon as it shows signs of submissive 
behavior thereby minimizing injury while still creating a stressor. Chronic social 
stress uses one of the most common human stressors, social conflict, and 
therefore provides a more realistic model of stress.  The model increased 
anhedonia, increased despair activity, and decreased exploratory behavior in the 
intruder rat (Rygula, Abumaria et al. 2005).  The effects of chronic social stress 





In the search for new antidepressant therapies, multiple animal models should be 
used to assess pharmaceutical efficacy.  While predictive tests provide a well-
validated method correlated with positive effects on human depression, they may 
fall short of identifying antidepressants with novel mechanisms.  Therefore, tests 
that exhibit face validity may be a good complement when exploring treatments 
or targets with unknown mechanisms.   
 
 
Emerging antidepressant treatments 
 
 
As it is increasingly clear that the pathophysiology of MDD goes far beyond the 
monaminergic system alone, advances in our understanding of the disorder are 
guiding the development of novel antidepressant classes.  The Sequenced 
Treatment Alternatives to Depression (STAR*D) clinical trial found that 37% of 
patients achieved remission with the selective-serotonin reuptake inhibitor (SSRI) 
citalopram.  Only half of the patients who remained depressed following the trial 
responded to three follow-up treatments involving medication switching and 
augmentation (Rush, Trivedi et al. 2006).  Current treatments take 2-5 weeks to 
alleviate depression symptoms and show high rates of relapse (Rush, Trivedi et 
al. 2006). Below, I characterized a number of novel potential targets and their 
shortcomings.  The lack of therapeutic success highlights the need for further 






A number of novel targets have emerged from the increased study of 
physiological abnormalities underlying MDD.  Among them are the amino acid 
neurotransmitters, glutamate and gamma aminobutyric adic (GABA), responsible 
for the large majority of neurotransmission in the brain.   Several studies 
implicate abnormal glutamatergic activity in the development of MDD (Krystal, 
Sanacora et al. 2002; Kugaya and Sanacora 2005; Pittaluga, Raiteri et al. 2007).  
In animal studies, there is evidence that enhanced glutamatergic drive 
contributes to stress-related neurotoxicity in the hippocampus (Sapolsky 2000).   
 
There is increased evidence from human post-mortem studies showing 
decreased glial cell numbers and density in a number of brain regions in 
depressed subjects compared to controls (Kugaya and Sanacora 2005; 
Rajkowska and Miguel-Hidalgo 2007; Bernard, Kerman et al. 2009).  This is 
important as glia are modulators of both the glutamatergic and GABAergic 
neurotransmitters systems (Araque and Perea 2004; Santello and Volterra 2009).  
Clinical evidence showed that antidepressants decreased glutamatergic 
transmission or indirectly affected N-methyl-D-aspartate (NMDA) glutamate 
receptor function (Feyissa, Chandran et al. 2009; Kucukibrahimoglu, Saygin et al. 
2009).  Also antidepressants increased GABA levels in cortical regions and 
decreased GABA deficits in depressed patients (Sanacora, Mason et al. 2002; 





The four potential targets for the glutamate system are the (1) ionotropic 
glutamate receptors, (2) NMDA receptors, (3) α-amino-3hydroxy-5-methyl-
isoxazole-4-propionic acid (AMPA) receptors, and (4) kainite (KA) receptors.  
AMPA and KA receptors are altered in animal models of depression and in 
depressed individuals.  Additionally, several compounds that alter AMPA and KA 
signaling result in antidepressant-like activity (Alt, Nisenbaum et al. 2006; Alt, 
Weiss et al. 2006; Bleakman, Alt et al. 2007; O'Neill and Witkin 2007).  However, 
no clinical data on these compounds is yet available.  Thus, compounds that 
target both NMDA receptors and metabotropic glutamate receptors as well as 
their clinical efficacy will be described below. 
 
NMDA receptors have gained increased support as novel therapeutic targets for 
mood disorders due to role of the receptor in learning, neuroplasticity, and 
neurotoxicity (Pittenger, Sanacora et al. 2007).  However, NMDA receptor 
activation is fairly complex.  Synaptic NMDA receptors activate transcription 
factors, MAPK and CREB, and subsequently increase BNDF expression to 
promote neuronal survival.  Conversely, extrasynaptic NMDA receptor activation 
increases cell death (Hardingham and Bading 2003; Hardingham 2006).  The bi-
directional modification of NMDA receptors may be an underlying mechanism for 
the regulation of synaptic remodeling.  Dysregulation of this NMDA receptor 
signaling and trafficking may contribute to the pathophysiology of mood disorders 





Clinical studies have shown a high correlation between antidepressant efficacy 
and an antidepressant’s ability to modify NMDA receptor binding affinity (Paul, 
Nowak et al. 1994; Skolnick 1999).  Furthermore, clinical studies have also 
shown that a single dose of the NMDA receptor antagonist, ketamine, caused a 
significant antidepressant response in depressed individuals.  However, most 
individuals treated with ketamine returned to pre-treatment depression rating 
scores within five days of the infusion (Berman, Cappiello et al. 2000; Zarate, 
Singh et al. 2006).  While ketamine has potential as a novel therapeutic for the 
treatment of depression, it produces unwanted side effects such as altered levels 
of consciousness, perceptual and cognitive disruptions, and hypertension.  
Additionally, it is not known whether chronic administration of the NMDA receptor 
antagonist could have detrimental effects on behavior and long-term neuronal 
survival (Olney 1994; Chen and Lipton 2006). 
 
Another glutamate-modulating drug, riluzole (Rilutek), currently approved for the 
treament of amyotropic lateral sclerosis (ALS) (Miller, Mitchell et al. 2007), has 
been implicated in its potential for mood disorder treatment.  Riluzole may act as 
a functional antagonist at GluRs to result in reduction of glutamate release 
(Benavides, Camelin et al. 1985; Debono, Le Guern et al. 1993).  Interestingly, 
riluzole increased BDNF expression in the hippocampus (Katoh-Semba, Asano 
et al. 2002).  Recent open-label clinical trials have resulted in positive effects on 
mood disorders (Mathew, Amiel et al. 2005; Zarate, Quiroz et al. 2005; 




in the trials remains small and no double-blind studies have been described to 
date.  Overall, members of the glutamatergic system have potential as targets for 
the treatment of depression.  While there is much supporting evidence for the 
role of GABAergic abnormality in both animal studies and in clinical observations 
(Bateson 2004; Choudary, Molnar et al. 2005; Russell, Carling et al. 2006; 
Sanacora and Saricicek 2007), benzodiazepines are not effective in the 
treatment of MDD. 
 
As HPA axis dysregulation has been consistently described in depression 
research, this system is an obvious target for novel therapeutics (Berger, Krieg et 
al. 1988; Heuser 1998).  Since depressed patients sometimes show excessive 
cortisol secretion and decreased negative feedback regulation (Ising, Lauer et al. 
2005), corticotropin-releasing factor (CRF) emerged as a novel target for 
antagonism.  Transgenic mice overexpressing CRF display depression-like 
behavior (Stenzel-Poore, Heinrichs et al. 1994).  Furthermore, clinical 
observations find that depressed patients have elevated levels of CRF in their 
cerebrospinal fluid.  These elevated CRF levels can be corrected by 
antidepressant treatment (Nemeroff, Bissette et al. 1991).  However, CRF 
activates two receptors (Reul and Holsboer 2002), CRF1 and CRF2.  CRF2 
studies resulted in conflicting observations. 
 
 CRF2 knockout mice exhibit increased anxiety-like behavior that can be 




infusion of a CRF2 antagonist caused decreased anxiety-like behavior (Valdez 
2006).  Thus, CRF1 is the primary target for antidepressant medication.  CRF1 
antagonists consistently showed increased antidepressant-like activity in animal 
models of depression after chronic, but not acute, treatment (Kehne and De 
Lombaert 2002; Kehne 2007).  Additionally, clinical trials investigating the 
efficacy of R121919, a CRF1 antagonist, found a significant reduction in anxiety 
and depression scores following administration (Zobel, Nickel et al. 2000; Zorrilla 
and Koob 2004).  Unfortunately, the CRF1 antagonist (Neurocrine, Inc.) also 
resulted in elevated liver enzymes in two subjects and resulted in discontinuation 
of the trials.  However, more trials using alternate CRF1 antagonists are currently 
underway. 
 
In addition to CRF1 antagonists, other HPA axis targets are being investigated.  
Specifically, metyrapone, an inhibitor of cortisol secretion, has been shown to 
increase expression of hippocampal and cortical BDNF in rats (Rogoz and 
Legutko 2005).  Additionally, clinical trials have found that metyrapone is an 
effective adjunct therapy in the treatment of MDD and metyrapone was well 
tolerated in humans (O'Dwyer, Lightman et al. 1995; Jahn, Schick et al. 2004).  It 
accelerated the onset of antidepressant action when used in combination 
standard serotonergic antidepressants.  Despite the positive results of these 
clinical trials, further studies confirming the use of metyrapone as a stand-alone 





Our lab has also shown that HPA axis dysregulation involving glucocorticoid 
receptor overexpression in transgenic mice caused a mouse-model of increased 
emotional lability.  These animals have increased anxiety-like and depression-
like behavior as well as increased sensitivity to antidepressants (Wei, Lu et al. 
2004).  Clinical studies show that mifepristone (RU486), a glucocorticoid receptor 
antagonist, provided improvement in depression-like symptoms in psychotic 
depression (Belanoff, Rothschild et al. 2002; DeBattista and Belanoff 2006).  
However, multiple phase III trials for MDD with RU486 failed to reach endpoints 
of rapid and sustained response, defined as a 50% or greater decrease in 
Brief Psychiatric Rating Scale (Nihalani and Schwartz 2007). 
 
The melatonin system is another potential target for MDD therapeutics.  It is 
known that melatonin is thought to be a regulator of human sleep/wake cycles 
(Pandi-Perumal, Zisapel et al. 2005).  Melatonin is considered a biochemical 
transducer that relays photoperiodic information to all cells in the body. Melatonin 
is secreted at night and suppressed during the day monteleone.  Both the 
concentration and the timing of melatonin release are dysregulated in depression 
(Rubin, Heist et al. 1992; Wetterberg, Bergiannaki et al. 1999).  Administration of 
melatonin itself does not have an effect on depression in humans (Carman, Post 
et al. 1976).  However, recent studies show that agomelatine, a melatonin 
receptor and 5HT2C receptor antagonist, have antidepressant-like and anxiolytic 
effects in animal models of depression.  However, it cannot be ruled out that the 




antagonist properties of agomelatine (Papp, Gruca et al. 2003; Millan, Brocco et 
al. 2005).  Agomelatine has also shown promising effects on depression in 
clinical trials, and the melatonin agonist showed a more rapid onset of effect than 
traditional antidepressants (Kennedy and Emsley 2006; Montgomery and Kasper 
2007).  While early results are promising, the long-term efficacy and tolerance of 
agomelatine must still be explored.  Melatonin has a number of other targets, 
including the immune system, which may be adversely affected by prolonged 
agomelatine administration. 
 
While recent studies, encompassing better models of the pathophysiology of 
MDD, have resulted in a number of potential targets, the yield of new effective 
therapeutics has been fairly low.  However, developing an arsenal of therapeutics 
against different targets may eventually allow patients, who are resistant to 
current therapeutics, the potential for more personalized medicine.  The potential 
for novel neurotrophic targets, particularly FGF, will be discussed throughout the 
following series of studies. 
 
To this end, the second chapter of this dissertation examines the potential for 
exogenous administration of FGF9 in vivo and identifies important variables to 
consider when administering growth factors.  Following these studies, chapter 
three characterizes the effect of both acute and chronic administration of FGF9 
on depression-like and anxiety-like behavior.  In addition, the effect of chronic 




hippocampus is examined.  Finally in chapter four, I examine whether FGF9, 
FGF2, or FGFR1 have circadian variations in expression throughout a 24-hour 
light-dark cycle.  I also test whether exogenous administration of FGF2 affects 













The structure of FGF9 consists of twelve antiparallel β-strands flanked by an 
amino and a carboxyl terminal.  The β1- β2 loops and parts of the β10 and β12 
loop make up the binding site for heparin sulphate glycosaminoglycan 
(HSGAGs).  HSGAGs aid in the ligand-receptor binding of FGF-FGFR by binding 
to both simultaneously.  The β9- β10 low affinity loops interacts directly with the 












The overlay of the structural backbones of FGF2 (brown) and FGF9 (blue) 
highlights that the “low affinity loop” of FGF2 is shorter than that of FGF9.  This 
loop is responsible for the receptor binding specificity of the FGF ligand.  This 
“low-affinity” loop decreases the ability of FGF9 to interact with FGFR1 and 
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Critical experimental considerations for determining the effects of 







In this set of experiments, we examined a number of variables that are crucial to 
determining the effects of fibroblast growth factor-9 (FGF9) on affective behavior.  
Animals were injected on post-natal day two (PND2) to determine whether a 
single early-life subcutaneous (s.c.) injection had long-lasting effects on adult 
behavior as was observed with FGF2.  We observed no significant changes in a 
battery of adult behaviors.  We also tested whether an intraperitoneal (i.p.) 
injection of FGF9 had an effect on anxiety-like or depression-like behavior.  We 
found no effect on anxiety-like or depression-like behavior following an acute 
injection via this route of administration.  By contrast, we observed that an acute 
intracerebroventricular (i.c.v.) microinjection of FGF9 increased depression-like 
behavior during the first half of the light-cycle.  The depressionogenic effect was 
sensitive to time manipulations.  Testing during the second-half of the light-cycle 
revealed an overall decrease in escape activity that may mask the decrease in 
escape activity observed in the first-half of the light-cycle.  We further showed 
that the increase in depression-like behavior after an acute microinjection of 
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FGF9 did not persist past 48 hours.  Finally, we demonstrated that a novel 
peptide targeted at the “low-affinity loop” (LAL) of FGF9 did not alter depression-
like behavior.  These findings provided important information about the route of 
administration for the subsequent FGF9 studies (described in Chapter 3). 
Furthermore, the differential effect of timing provided the rationale for assessing 
rhythmicity of FGF system gene expression (described in Chapter 4).  Thus, this 
set of experiments acted as an experimental framework for the formal studies of 






Our research group, as part of a larger consortium, was the first to show that 
fibroblast growth factor family gene expression was dysregulated in post-mortem 
brain tissue from individuals diagnosed with major depressive disorder (MDD) 
(Evans, Choudary et al. 2004).  Subsequently, other studies have confirmed that 
FGF2 gene expression was downregulated while FGF9 expression was 
significantly upregulated in a number of cortical and subcortical brain regions in 
MDD (Sibille, Arango et al. 2004; Evans, Choudary et al. 2004b; Gaughran, 
Payne et al. 2006; Tochigi, Iwamoto et al. 2008).  Particularly, FGF9 is the single 
growth factor that is consistently upregulated in multiple brains regions across 
both Affymetrix and Illumina microarray platforms (Evans, Choudary et al. 2004; 
Evans, Choudary et al. 2004b).  To this end, we have hypothesized that 
members of the FGF family, especially FGF9, may be potential targets for the 
therapeutic treatment of mood disorders. 
 
Recently, we have shown that chronic microinjections of FGF2 had 
antidepressant-like effects on behavior (Turner, Gula et al. 2008). Also, chronic 
intraperitoneal injections of FGF2 can decrease anxiety-like behavior as 
measured by increased time spent in the light portion of the light-dark box 
(Perez, Clinton et al. 2009). While we have previously studied the role of 
exogenous FGF2 in affective behavior, the following experiments were our first 
attempts to characterize behavioral effects of exogenous FGF9 on rats.  The 
series of studies parallels early attempts to administer FGF2 in vivo (Wagner, 
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Black et al. 1999; Deguchi, Naito et al. 2000; Wu, Song et al. 2002; Perez, 
Clinton et al. 2009; Turner, Capriles et al. 2009), and our studies characterized 
the most effective method for FGF9 delivery in vivo to observe effects on 
affective behavior. In order to understand the effects and timing of FGF9 
administration, we tested both persistence of FGF9 effects on affective behavior 
(Lucki 1997) and manipulated the route of administration and the timing of the 
injection.  These results gave us a better understanding of the variables that 
were important for subsequent FGF9 studies (Chapters 3 and 4). 
 
Although not much is known about the physiological effects of FGF9, FGF9 is 
expressed, preferentially in neurons, throughout the human brain in cerebral 
cortex, hippocampus, motor nuclei of the brain stem, substantia nigra, and 
Purkinje cell layer (Todo, Kondo et al. 1998).  FGF9 also has moderately strong 
gene expression in the rat hippocampus and cerebral cortex (Tagashira, Ozaki et 
al. 1995).  FGF9 and its subfamily members (FGF16 and FGF20) are unique 
from other members of the FGF family in that, despite the lack of a typical 
secretion signal, they are still secreted like members that have a typical signal 
sequence (Miyamoto, Naruo et al. 1993).  Besides MDD, FGF9 expression is 
upregulated in other brain disorders such as Alzheimer’s Disease (Nakamura, 
Arima et al. 1998) and amyotrophic lateral sclerosis (ALS) (Nakamura, Arima et 
al. 1998).  Furthermore, single nucleotide polymorphisms (SNPs) in FGF20, a 
member of the FGF9 subfamily, have recently been linked to the increased 
expression of α-synuclein in Parkinson’s disease (PD).  FGF20 is currently being 
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considered as a potential therapeutic target for treatment of PD (Gao, Scott et al. 
2008; Wang, van der Walt et al. 2008).   
 
Since FGF9 was consistently upregulated in multiple brain regions of post-
mortem tissue of individuals diagnosed with MDD, we hypothesized that FGF9 
may be a potential therapeutic target.  To this end, we designed a peptide 
antagonist to the LAL of FGF9.  The LAL is primarily responsible for the 
sequence specifity needed for FGF9 to bind to its primary receptor, FGFR3 
(Hecht, Zimmerman et al. 1995).  Therefore, the antagonist should decrease 
FGF9 binding affinity and, subsequently, downstream activation of FGF 
receptors.  In order to characterize the effects of the LAL antagonist in vivo, we 
acutely microinjected rats with multiple doses of the antagonist and measured its 
effect on depression-like activity. 
 
 






All Sprague-Dawley rats (Charles River Laboratory, MA) were treated in 
accordance with the National Institutes of Health Guidelines on Laboratory 
Animal Use and Care and in accordance with the guidelines set by the university 
committee on use and care of animals at the University of Michigan.  The 
animals were maintained under conditions of constant temperature (21 +/- 2°C) 
 63 
and a 12-hour/12-hour light-dark cycle with access to food and water ad libitum.  
All animals were allowed one week to acclimate to housing conditions before any 
experiments were performed.  All animals were pair-housed during adulthood 
with the exception of animals that were cannulated for acute microinjections, they 
were singly housed post-operatively and throughout the acute injections studies. 
 
 
Early-life subcutaneous injection of FGF9 
 
 
Outbred pregnant females (Charles River Laboratory, Wilmington, MA) were 
housed individually under conditions of constant temperature (21 +/- 2°C) and a 
12-hour/12-hour light-dark cycle with access to food and water ad libitum  
throughout their pregnancy, birth, and weaning period.  Pups were culled to four 
male and four females on PND2.  Immediately after the culling, animals were 
injected with either FGF9 (20ng/g in 50µl 0.1M PBS w/ 1% BSA, s.c.; Cell 
Sciences) or vehicle (0.1M PBS w/ 1% BSA, s.c.) (Turner, Capriles et al. 2009). 
Group assignments were counterbalanced within each litter.  Animals were 
weaned on PND21 and males were separated and housed two per cage for the 
remainder of the experiment.  The behavior of adult animals, two to three months 
old, was evaluated with a battery of tests: locomotor activity, elevated plus maze 
(EPM), forced swim test (FST), and Morris water-maze navigation task 




Adult intraperitoneal injection of FGF9 
 
 
Animals (250-300g) were housed two per cage under normal housing conditions.  
Animals were injected with either FGF9 (5ng/g in 50µl 0.1M PBS w/ 1% BSA, i.p.; 
Cell Sciences) or vehicle (0.1M PBS w/ 1% BSA, i.p.).  Animals were assessed 
for anxiety-like or depression-like behavior on the EPM or FST (described 
below), respectively.  For the FST, animals received three injections: one 
immediately after the Day One pre-test swim, one eight hours following the pre-
test swim, and one immediately before the Day Two test swim.  Animals were 
rested five days after Day Two of the FST before they were tested on the EPM.  
The animals were counterbalanced and injected with one injection of FGF9 
(5ng/g, i.p.) or vehicle (0.1M PBS w/ 1% BSA, i.p) and immediately tested 15 
minutes after the injection. 
 
 




Rats were anesthetized with isofluorane and were implanted with a guide 
cannula (22-gauge, Plastics One Inc., VA).  The cannula was placed in the left 
lateral ventricle (coordinates from bregma: AP -1.1; ML +1.3; DV -3.0) using a 
small-animal stereotaxic instrument.  The guide cannula was anchored to the 
skull using dental cement and was fitted with an obturator.  Animals received a 
microinjection using a 28-gauge injector cannula extending 1.5mm below the tip 
of the guide.  The microinjection cannula was connected by PE-20 tubing to a 
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Hamilton syringe mounted on a syringe pump (Harvard Apparatus, MA) and rats 
were microinjected with either recombinant human FGF9 (200ng, i.c.v) (Cell 
Sciences, MA) or the vehicle (artificial extracellular fluid (aECF), i.c.v)  with 
100µg/ml bovine serum albumin (Kuhn, Winkler et al. 1997; Cambon, Hansen et 
al. 2004).  
 
To measure the long-term effects of an acute microinjection of FGF9, animals 
were injected once after Day One of the FST between 0800 h and 1200 h, and 
were allowed to wait 48 hours until the next swim on Day Three.  To determine 
whether FGF9 had an effect on the FST from 1300 h – 1700 h, animals were 
injected immediately after Day One of the FST between 1300 h and 1700 h.  
Animals were evaluated by a Day Two (24 hours later) swim trial between 0800 h 
and 1200 h.   
 
For, LAL peptide antagonist studies animals received an injection of the LAL 
peptide antagonist (YKHUDTGRRYY) (0.5 µg, 5 µg, or 50 µg, i.c.v.) or vehicle 
(aECF, i.c.v). LAL peptide antagonist study animals were injected once 
immediately after Day one of the FST between 0800 h and 1200 h and then 
tested 24 hours later on Day Two.  The total volume injected for all microinjection 
studies was 8µl infused at a rate of 1µl /min in freely moving animals. The 







PND2 animals injected with FGF9 (20ng/g in 50µl 0.1M PBS w/ 1% BSA, s.c) or 
vehicle (50µl 0.1M PBS w/ 1% BSA, s.c) were allowed to age under normal 
housing conditions.  At two months of age, animals were tested for differences in 
locomotor activity.  The rats were placed in a 43 x 21.5 x 25.5cm acrylic cage 
with stainless steel floor gridding.  Horizontal and vertical (rearing) locomotor 
activity was monitored every five minutes for one hour by two panels of 
photocells that recorded beam breaks.  For total locomotion, horizontal and 
vertical components were added together and an average was found for each 
animal and group.  The locomotion-testing rig and motion-recording software 
were developed in-house at the University of Michigan.  All locomotor testing 
took place between 0800 h and 1200 h. 
 
 
Morris water-maze navigation task 
 
 
PND2 animals injected with FGF9 (20ng/g in 50µl 0.1M PBS w/ 1% BSA, s.c) or 
vehicle (50µl 0.1M PBS w/ 1% BSA, s.c) were allowed to age under normal 
housing conditions.  At three months of age, animals were tested for differences 
in spatial navigation of the Morris water-maze.  The water-maze was a circular 
tank made from black polyethylene and was 1.5 m in diameter and 0.5 m in 
height.  The tank was filled with lukewarm water and a 10cm Plexiglas circular 
platform, 1.5cm below the water level, was used as an escape platform.  The 
tank was placed in the middle of a room that contained visual extra-maze cues.  
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The platform was located at a predetermined direction (north, east, south, or 
west), and each animal was placed into the tank facing the wall.  Escape latency 
(time between introduction to maze and climbing on the escape platform) was 
recorded for each animal.    
 
A trial lasted until the animal climbed on the escape platform, or until two minutes 
had elapsed at which point the animal was placed on the platform. Animals were 
allowed to stand on the escape platform for 30 seconds following the trial.  
Testing continued for five days, four trials per day with each trial starting in a 
different quadrant.  Escape latencies were averaged across three trials to yield 
values for trial blocks.  All testing was done in a dimly lit room (~40 lux) between 
0800 h and 1200 h. 
 
 
Forced swim test   
 
 
Day One of the FST consisted of a fifteen minute pre-test swim and Day Two 
consisted of a five minute test swim which provides valuable information on the 
animals’ reaction to the second day of stress (Porsolt, Bertin et al. 1977; Porsolt, 
Deniel et al. 1979).  The Day One pre-test swim aids in the development of 
immobility during the subsequent Day Two test session and increases the 
sensitivity to antidepressants (Borsini, Lecci et al. 1989).  A modified version of 
the FST was used to test if an acute injection of FGF9 (200 ng, i.c.v.) had a long-
lasting effect on depression-like behavior.  This modification involved repeated 
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testing of the same animals on Day Three and Day Six, instead of Day Two 
(Hoshaw, Malberg et al. 2005).  Animals were placed in cylinders filled with water 
at a depth in which the rat’s tail could not touch the bottom with a temperature of 
25°C.  Water was changed between animals and all sessions were recorded 
from above by a video camera.   
 
All FST swim sessions took place between 0900 h and 1200 h except in the 
study to determine whether FST activity can be tested in the second-half of the 
light-cycle (1300 h to 1700 h). The videotaped activity was scored with the 
following considerations:  (1) swimming consisted of horizontal movement 
throughout the cylinder, (2) climbing was defined by vertically-directed movement 
of forepaws against the wall of the cylinder, and (3) immobility was defined as 
floating or the minimal movement necessary to keep the head above water level.  
The FST has high predictive validity for antidepressant activity and animals 
display “despair” behavior as indicated by a decrease in escape behaviors  
(Lucki 1997).  Escape activity was calculated as the percent total duration spent 
swimming and percent total duration spent climbing.    Percent total duration of 
swimming, climbing, and immobility episodes was scored using The Observer 




Elevated plus-maze   
 
 
The EPM was used to test the anxiety-like behavior of the rats by using their 
natural aversion to high open spaces.  The maze consists of black Plexiglas with 
four elevated arms (70cm from the floor, 45cm long, and 12 cm wide).  The EPM 
has two arms enclosed by 45cm-high wall and two open arms arranged in the 
shape of a cross.  At the intersection of the four arms of the maze, a 12 x 12cm 
square allowed access to all four arms.  During the five minute test period, the 
room was dimly lit (~40 lux), and behavior was monitored using a computerized 
video tracking system (Noldus Ethovision).  At the start of the five minute test, the 
rat was placed in the center square platform facing a closed arm.  The tracking 
system recorded the latency to enter the open arm, the amount of time spent in 
open and closed arms, and the time spent in the center square.  After every 
animal, the testing apparatus was wiped down with 30% ethanol. Animals that 
spent a greater percentage of time in the closed arms were considered more 
anxious while, conversely, animals that spent a greater percentage of time 
exploring the open arms were considered less anxious. 
 
 
Statistical analyses   
 
 
The Morris water-maze navigation experiment using animals injected with FGF9 
or vehicle in early-life were analyzed by a two-way repeated measures analysis 
of variance (ANOVA). The FST experiment using animals that were microinjected 
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with FGF9 or vehicle, at either 0800 h -1200 h or 1300h -1700 h, was analyzed 
by a two-way ANOVA. The FST experiment, using animals that were 
microinjected with different doses of the LAL antagonist, were analyzed by a one-
way ANOVA followed by Fisher’s least significant difference post hoc analysis.  
All other behavioral data was analyzed by a Student’s t-test. Data are presented 
as mean +/- standard error of the mean with statistical significance set at  










Animals were injected with FGF9 (20ng/g in 50µl 0.1M PBS w/ 1% BSA, s.c) or 
vehicle (0.1M PBS w/ 1% BSA, s.c) and were tested for a battery of behaviors.  
Student’s t-test showed no significant difference in locomotor activity including 
rearing (t(15) = 0.65, p = 0.53), horizontal movement (t(15) = 0.90, p = 0.38), and 
total movement (t(15) = 0.80, p = 0.44) in animals injected with FGF9 compared to 
vehicle controls (Figure 2-1A).  There were also no significant differences in 
anxiety-like behavior as evidenced by no dissimilarity in percent time spent on 
open (t(18) = 0.73, p = 0.48) or closed arms (t(18) = 0.46, p = 0.65) of the EPM in 
animals injected with FGF9 compared to vehicle controls (Figure 2-1B).  
Furthermore, there was no significant change in depression-like behavior as 
evidenced by no differences in percent time spent climbing (t(18) = 0.48, p = 0.63), 
 71 
swimming (t(18) = 0.64, p = 0.53), or immobile (t(18) = 0.47, p = 0.64) in the FST in 
animals injected with FGF9 compared to vehicle controls (Figure 2-1C).  Finally, 
analysis by a two-way repeated measures ANOVA showed no significant 
differences in spatial memory as animals did not differ in their latency time to find 
the hidden platform in the Morris water-maze navigation task (F(5,68) = 2.02, p = 
0.09) for animals injected with FGF9 compared to vehicle controls (Figure 2-1D).   
 
 
An acute intraperitoneal injection in adult rats had no effect on anxiety-like 
or depression-like behavior 
 
 
Animals received an injection of FGF9 (5ng/g in 50µl 0.1M PBS w/ 1% BSA, i.p.) 
or vehicle (50µl 0.1M PBS w/ 1% BSA, i.p.).  Student’s t-test showed no 
significant changes in anxiety-like behavior 15 minutes after an acute injection as 
shown by the absence of differences in percent time spent on the open arm  
(t(13) = 1.30, p = 0.22) or closed arm (t(13) = 0.06, p = 0.95) in the EPM in animals 
injected with FGF9 compared to vehicle controls (Figure 2-2A).  There were also 
no differences in depression-like behavior after an acute injection following Day 
One of the FST, as evidenced by no group differences in percent time spent 
climbing (t(13) = 1.5, p = 0.16), swimming (t(13) = 0.91, p = 0.38), or immobile 
(t(13) = 0.27, p = 0.79) in animals injected with FGF9 compared to vehicle controls 
(Figure 2-2B). 
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Acute microinjection of FGF9 increased escape activity in the first-half of 
the light cycle 
 
 
Animals were microinjected with FGF9 (200ng, i.c.v.) or vehicle (aECF, i.c.v.). 
Animals injected and tested in the first-half of the light-cycle (0800 h -1200 h) 
showed a significant increase in depression-like behavior in the FST as 
evidenced by a decrease in percent time spent performing escape activity (F(1,20) 
= 12.89, p < 0.003) in animals microinjected with FGF9 compared to vehicle 
controls (Figure 2-3A).  There was a significant decrease in escape activity (F(1,20) 
= 27.21, p < 0.001) observed in vehicle controls tested and injected during the 
second-half of the light-cycle (1300 h – 1700 h) compared to vehicle controls 
tested and injected during the first-half of the light-cycle (0800 h - 1200 h) (Figure 
2-3A).   Animals injected and tested during the second-half of the light-cycle 
(1300 h -1700 h) showed no significant increase in depression-like behavior as 
evidenced by no differences in percent time spent climbing (t(14) = 0.67, p = 0.51), 
swimming (t(14) = 0.54, p = 0.60), or immobile (t(14) = 20.21, p = 0.84) in the FST in 
animals microinjected with FGF9 compared to vehicle controls (Figure 2-3B). 
 
 
An acute intracerebroventricular injection of FGF9 did not have lasting 
effects on depression-like behavior 
 
 
Animals received a single microinjection of FGF9 (200ng, i.c.v.) or vehicle 
(aECF, i.c.v.). A swim-trial two days after the Day One pre-test swim in the FST 
resulted in no significant differences in percent time spent climbing (t(18) = 0.79, p 
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= 0.44), swimming (t(18) = 0.21, p = 0.65), or immobile (t(18) = 0.14, p = 0.89) on 
Day Three compared to vehicle controls (Figure 2-4A).  A swim-trial five days 
following the Day One pre-test swim showed no long-lasting effect of FGF9 
microinjection on depression-like behavior in the FST as evidenced by no 
differences in percent time spent climbing (t(1,18) = 0.69, p = 0.50), swimming (t(18) 
= 0.22, p = 0.83), or immobile (t(18) = 0.32, p = 0.75) on Day Six compared to 
vehicle controls (aECF, i.c.v.) (Figure 2-4B). 
 
 




Animals were microinjected once with the LAL peptide antagonist (0.5 µg, 5 µg, 
or 50 µg, i.c.v.) or vehicle (aECF, i.c.v.).  There was no overall effect of the LAL 
peptide antagonist on depression-like activity as evidenced by no dissimilarity in 
percent time spent climbing (F(3,35) = 2.23, p = 0.10), swimming (F(3,35) = 0.12, p = 
0.95), or immobile (F(3,35) = 0.59, p = 0.63) in the FST compared to vehicle 






The results of these studies show a number of negative results that provide the 
framework for the formal experiments that follow in Chapters 3 and 4.  We found 
that: (1) a single PND2 injection of FGF9 did not alter adult locomotor activity, 
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anxiety-like behavior, depression-like behavior, or spatial navigation memory, (2) 
an acute intraperitoneal injection of FGF9 did not alter anxiety-like or depression-
like behavior, (3) an acute microinjection of FGF9 had no long-lasting effects on 
depression-like behavior,  (4) an acute microinjection of FGF9 increased 
depression-like behavior preferentially in the first-half of the light cycle, and (5) an 
acute microinjection of a peptide antagonist targeted to the low-affinity loop of 
FGF9 had no effect on depression-like behavior.  These findings show that the 
method and timing of FGF9 injection are important to the evaluation of the effect 
of FGF9 on affective behavior.  The single positive finding in which an acute 
microinjection of FGF9 increased depression-like behavior in adult rats, indicated 
that we were in an effective dose range to effect emotional behavior. 
 
In contrast to these results, a single PND2 subcutaneous injection of FGF2 
altered adult behavior resulting in a long-lasting increase in cocaine-self 
administration (Turner, Capriles et al. 2009).  A single subcutaneous PND2 
injection of FGF2 also resulted in molecular changes as evidenced by altered 
hippocampal cell proliferation and gene expression (Turner and Inui, unpublished 
data).  Other labs have shown that, a single injection of FGF2 (20ng/g s.c.), 
facilitated neurogenesis in rats (Cheng, Black et al. 2002), enhanced long-term 
extinction of fear and reduced reinstatement (Graham and Richardson 2009), 
and enhanced long-term memory (Graham and Richardson 2009).  
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However, no changes in adult behavior were observed in animals injected with a 
single PND2 subcutaneous injection of FGF9 (20ng/g).  It is possible that FGF9 
requires a higher concentration than FGF2 to observe long-lasting developmental 
effects. Alternatively, as evidenced by our further peripheral studies, FGF9 may 
not cross the blood brain barrier (BBB).  Finally, we may not have measured the 
appropriate behavioral or functional endpoint, as we did not assess drug-taking 
behavior or hippocampal morphology. 
 
An acute peripheral injection of FGF2 increased anxiety-like behavior (Perez 
2009), and chronic peripheral FGF2 injections decreased anxiety-like behavior 
(Perez, Clinton et al. 2009). However, there was no effect of FGF9 on behavior 
after a peripheral injection of FGF9.  While it is known that FGF2 can cross the 
BBB (Deguchi, Naito et al. 2000; Wu, Song et al. 2002), it is difficult to know how 
much of the peripherally administered FGF2 is reaching the brain.  It is a 
possibility that FGF9 did not cross the BBB or an effective dose was not used. 
Therefore, we decided to microinject directly into the left lateral ventricle of the 
brain.  While we are not certain how far FGF9 diffuses after this microinjection, it 
is likely that a number of brain regions involved in mood disorders are affected by 
the intracerebroventricular administration of FGF9.  Microinjection into the lateral 
ventricle also minimizes damage caused by directly injecting into the 
hippocampus.  We have preliminary data indicating that direct microinjection of 
vehicle into the dentate gyrus increased expression of FGF2, FGF9, and FGFR1 
(Eren-Kocak E. 2009). 
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We observed an increase in depression-like behavior following an acute 
microinjection of FGF9.  This result led to the extensive studies described in 
Chapter 3. Other studies have shown that a single microinjection of other growth 
factors, insulin-like growth factor-1 (IGF1) and brain-derived neurotrophic factor 
(BDNF), decreased depression-like behavior for up to five days after the initial 
Day One swim in the FST (Hoshaw, Malberg et al. 2005).  We did not find a 
persistent increase in depression-like behavior in the FST after an acute injection 
of FGF9.  The half-life of FGF9 in the brain may be shorter than that of other 
growth factors, including FGF2 (Riva, Molteni et al. 1996).  Conversely, 
increased depression-like behavior may only occur up to 24 hours after 
microinjection.  Regardless of the mechanism, it is important to know that the 
effect of FGF9 was not long-lasting to inform future experiments. 
 
While trying to determine if splitting groups and testing half in the first-half of the 
light-cycle and half in the second-half of the light-cycle would be experimentally 
sound, we observed that there was significant effect of time of day on escape 
activity in the FST. It is possible FGF9 has differential effects on depression-like 
behavior during the first-half of the light-cycle than during the second-half of the 
light-cycle.  This possibility led to the formal study of circadian variations of the 
FGF family in the adult hippocampus discussed in Chapter 4.   It is also possible 
that the decrease in escape activity in vehicle controls during the second-half of 
the light-cycle is masking the increase in depression-like behavior observed 
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when animals were tested and injected in the first half of the light-cycle.  While 
others have shown that animals have decreased escape activity in the active 
period compared to the inactive period (Kelliher, Connor et al. 2000), no one has 
shown a decrease in escape activity in the second-half of the light-cycle.  This 
timing information is important to keep in mind for all experiments involving the 
FST for measurement of increased depression-like behavior.  
 
Finally, we synthesized a potential peptide antagonist to the LAL of FGF9.  This 
loop is crucial to the identity of the FGF9 ligand and provides the basis for its 
preferential activation of FGFR3 (Hecht, Adar et al. 2001).  The peptide was 
developed based on structural targeting and was no verified by in vitro studies.  
While we did not observe an effect of this peptide antagonist on depression-like 
behavior, this result may suggest that the effect of FGF9 on depression-like 
behavior is not mediated through activation of FGFR3.  FGF9 may be acting as a 
“physiological antagonist” to FGF2 by direct downregulation of FGFR1 
expression or by inhibition of astrocytic differentiation.   More work characterizing 
potent inhibitors of FGF9 in vitro must be done before further in vivo studies can 
be tested.   
 
In conclusion, this set of results highlighted the importance of central 
administration of FGF9 to observe effects on affective behavior in the adult rat.   
Furthermore, behavioral testing should be consistently performed in the first-half 
of the light-cycle to detect behavioral effects of FGF9.  Finally, targeting the LAL 
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loop of FGF9 did not alter depression-behavior, however targeting other FGF9-
specific sequences may lead to development of a novel therapeutic for the 
treatment of mood disorders. 
 
While a number of the studies in this chapter show negative results, these 
findings were a logical series of studies to increase understanding of the 
conditions necessary for detecting FGF9 effects on behavior.  Observations of 
increased depression-like behavior through central microinjections led to a formal 
series of studies characterizing the exogenous administration of FGF9 (Chapter 
3).  Observations of time-sensitive behavior led to formal studies of circadian 
variation of the FGF family in circadian variations of expression and behavior 













A)   An early-life injection of FGF9 (20ng/g, s.c.) had no effect on rearing, 
horizontal, or total locomotor activity in adult rodents (n= 7-10 animals per group).  
B)  An early-life injection FGF9 (20ng/g, s.c.)  had no effect on anxiety-like 
behavior as shown by no differences in percent time spent in the open or closed 
arms on the elevated plus-maze compared to vehicle control (n = 10 animals per 
group). 
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Figure 2-1 (continued):  An early-life subcutaneous FGF9 injection had no 









C)   An early-life injection of FGF9 (20ng/g, s.c.) had no effect on depression-like 
behavior in the forced swim test as shown by no differences in percent time 
spent climbing, swimming, or immobile in the forced swim test (n= 10 animals per 
group).  D)  An early-life injection of FGF9 (20ng/g, s.c.) had no effect on spatial 
memory as shown by no differences in time to platform in the Morris water-maze 
navigation task compared to vehicle controls (n= 10 animals per group). 
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A)   An acute injection of FGF9 (5ng/g, i.p.) had no effect on anxiety-like behavior 
as shown by no differences in percent time spent in the open or closed arms on 
the elevated plus-maze compared to vehicle controls (n= 7-8 animals/group). B)  
Three acute injections of FGF9 (5ng/g, i.p.) had no effect on depression-like 
behavior as shown by no differences in percent time spent climbing, swimming, 
or immobile in the forced swim test compared to vehicle controls (n= 7-8 animals 
per group). 
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Figure 2-3: An acute microinjection of FGF9 administrated during the first-
half of the light-cycle increased depression-like behavior. FGF9 
administered in the second-half of the light-cycle had no effect on 






A)  A significant decrease in escape activity was observed when FGF9 was 
microinjected between 0800 h and 1200 h and animals were tested on Day 1 and 
Day 2 between 0800 h and 1200 h compared to vehicle controls; ** p < 0.005, 
(n= 11 animals per group).  A significant decrease was observed in escape 
activity in vehicle control animals when animals were microinjected and tested 
between 1300 h and 1700 h compared to vehicle controls (aECF, i.c.v.) tested 
and microinjected between 0800 h and 1200 h; ***p < 0.001 (n= 8-11 animals per 
group). B) An acute microinjection of FGF9 (200ng, i.c.v.) did not have an effect 
on depression-like behavior in the forced swim test compared to vehicle controls 
(aECF, i.c.v.)  (n= 8 animals per group).  
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Figure 2-4: An acute intracerebroventricular injection of FGF9 did not have 







A)   An acute microinjection of FGF9 (200ng, i.c.v.) did not result in a persistent 
increase in depression-like behavior as shown by no differences in percent time 
spent climbing, swimming, or immobile two days after Day One of the forced 
swim test compared to vehicle controls (aECF, i.c.v.) (n= 10 animals per group). 
B) An acute injection of FGF9 (200ng, i.c.v.) did not result in a persistent 
increase in depression-like behavior as shown by no differences in percent time 
spent climbing, swimming, or immobile five days after Day One of the forced 
swim test compared to vehicle controls (aECF, i.c.v.) (n= 10 animals per group). 
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Figure 2-5:  An acute microinjection of a novel peptide designed to target 





An acute microinjection of the low-affinity loop antagonist (0.5 µg, 5 µg, or 50 µg, 
i.c.v.) did not have an effect depression-like behavior in the forced swim test 
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A novel role for fibroblast growth factor-9 in anxiety-like  






Human post-mortem studies have shown that fibroblast growth factor-9 (FGF9) 
gene expression was upregulated in multiple brain regions in individuals 
diagnosed with major depressive disorder (MDD).   While recent research 
implicates the fibroblast growth factor (FGF) family in mood disorders, relatively 
little is known about the role of FGF9 in response to stress or in emotional 
reactivity.  Initially, we investigated whether repeated social stress would alter the 
expression of FGF9 in the hippocampus. Repeated social stress increased 
rodent avoidance behavior and increased FGF9 gene expression.  We then 
assessed the behavioral effects of acute FGF9 microinjections.  Acute 
intracerebroventricular (i.c.v.) administration of FGF9 resulted in a dose-
dependent decrease in anxiety-like behavior and an increase in depression-like 
behavior.  Using the effective doses from the acute study, we then tested the 
effect of chronic microinjections on both behavior and alterations of FGF family 
gene expression in the hippocampus.  Chronic microinjections of FGF9 reversed 
the anxiety-like response seen in the acute microinjection studies, from anxiolytic 
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to anxiogenic, and maintained the increase in depression-like behavior.  Also, 
chronic microinjections of FGF9 decreased FGFR1 gene expression in the 
dentate gyrus of the hippocampus.  These findings support the role of FGF9 as a 
a responder to stress, a modulator of affective behavior, and a potential 





The discovery of molecular signatures and investigation of expression 
dysregulation in mood disorders may lead to targeted therapeutic treatments. 
Our lab, as part of a larger consortium, used microarray technology in human 
post-mortem studies on individuals diagnosed with MDD.  We had previously 
revealed dysregulation of FGF family gene expression in both cortical and 
subcortical brain regions (Evans, Choudary et al. 2004; Evans, Choudary et al. 
2004b; Akil, Evans et al. 2008).  Recently, independent efforts have confirmed 
changes in the FGF system in the post-mortem tissue of depressed individuals 
(Sibille, Arango et al. 2004; Aston, Jiang et al. 2005; Gaughran, Payne et al. 
2006; Tochigi, Iwamoto et al. 2008).  Importantly, FGF9 gene expression was 
consistently upregulated in multiple brain regions of individuals diagnosed with 
MDD and verified across Affymetrix and Illumina array platforms. In this series of 
studies, we explore whether: (1) FGF9 expression can be upregulated by 
repeated social stress (2) FGF9 can act as a modulator of affective behavior, and 
(3) FGF9 may be a physiological antagonist to FGF2. 
 
It is difficult to determine whether the dysregulation of the FGF family contributes 
to the development of MDD or is a result of the disease process.  In addition to 
upregulation of FGF9, FGF2 was consistently downregulated in cortical and 
subcortical brain regions (Evans, Choudary et al. 2004).  We have recently 
investigated the response of FGF2 gene expression to social defeat and the 
effect of exogenous FGF2 on emotionality to better understand its potential as a 
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therapeutic agent (Turner, Calvo et al. 2008; Turner, Gula et al. 2008; Perez, 
Clinton et al. 2009).  FGF2 expression was decreased by social defeat, and 
exogenous administration of FGF2 has antidepressant-like effects in adult rats.  
However, no previous studies have focused on the function of FGF9 in affective 
behavior. The consistent upregulation of FGF9 gene expression may provide 
both a biomarker of MDD as well as a potential molecular target for therapeutic 
inhibition.  While little is known about the role of FGF9 in psychiatric illness, it is 
well-documented that the FGF family plays an important role in the development 
(Molteni, Lipska et al. 2001; Vaccarino, Ganat et al. 2001) and maintenance of 
the CNS (Mufson, Kroin et al. 1999; Perrone-Capano, Da Pozzo et al. 2000).  
Some of these CNS functions include cell proliferation, differentiation, and 
neurogenesis (Reuss and von Bohlen und Halbach 2003).   
 
FGF9 is expressed throughout the human and rat brain and is localized 
preferentially to neurons (Tagashira, Ozaki et al. 1995; Todo, Kondo et al. 1998) 
although it can be expressed in some oligodendrocyte and astrocyte cell 
populations (Nakamura, Todo et al. 1997; Colvin, Feldman et al. 1999; Garces, 
Nishimune et al. 2000).  The neuronal expression of FGF9 is thought to support 
neuronal survival through an autocrine/paracrine system.  A great deal is known 
about the signaling pathways of the FGF family in rats in which the 22 FGF 
ligands can bind to five different receptors (FGFR1-5) (Reuss and von Bohlen 
und Halbach 2003).  However, much work still needs to be done to understand 
the specificity and regulation of the signaling process.   
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Since stressful life events are thought to trigger the onset of depressive 
episodes, it is hypothesized that animal models of social stressors might lead to 
a better understanding of the molecular changes occurring in the brain during 
depression (Kendler, Karkowski et al. 1999).  In this study, we employed a 
repeated social stress paradigm (Miczek 1991; Kabbaj, Evans et al. 2004) to 
determine the effect of stress on FGF9 expression.  Animals exposed to 
repeated social stress showed increased anhedonia and neuroendocrine 
responses similar to those of depressed patients (Kudryavtseva, 
Bakshtanovskaya et al. 1991; Koolhaas, Meerlo et al. 1997).  The behavioral and 
endocrine changes caused by the social stress are often maintained long after 
the stressful events are over (Koolhaas, Meerlo et al. 1997; Von Frijtag, Reijmers 
et al. 2000).   
 
In addition to quantifying behavioral measures of depression, we also looked at 
changes in FGF9 expression in the hippocampus after repeated social stress. 
The hippocampus is considered key in modulating anxiety-like and depression-
like response (Kim and Yoon 1998; McEwen 1999; Kim and Diamond 2002).  
Previously, we found that FGF2 and FGFR1 mRNA expression was decreased in 
the hippocampus following acute social defeat (Turner, Calvo et al. 2008). 
Additionally, there is significant evidence of the impact of stress on the 
hippocampus as documented by electrophysiological, neuroanatomical, and 
cellular physiology studies (de Kloet, Joels et al. 2005). 
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As FGF2 was downregulated and FGF9 was upregulated in post-mortem tissue 
of patients diagnosed with MDD, it was hypothesized that FGF9 would have 
opposing behavioral effects in anxiety-like and depression-like behavior in rats.  
Recently, it has been shown that FGF9 regulated adult neural progenitor cells in 
vitro by inhibiting differentiation of glial fibrillary acid (GFAP)-expressing 
astrocytes, decreasing oligodendrocyte differentiation, and increasing generation 
of neural progenitors (Lum, Turbic et al. 2009).  By contrast, our lab has also 
shown that chronic FGF2 treatment increased GFAP-positive astrocyte formation 
(Perez, Clinton et al. 2009).    It is possible that FGF9 is acting as a naturally 
occurring antagonist to FGF2 by: (1) binding to and sequestering the ligand or (2) 
binding to the receptor and preventing its response to another molecule.  While 
FGF2 may act as an endogenous inhibitor of anxiety, FGF9 may be mediating 
the long-term anxiogenic and depression-like symptoms seen in MDD through 
endogenous antagonism of FGF2.   
 
 






Adult male Sprague-Dawley rats (Charles River Laboratories, Wilmington, MA), 
weighing between 220-250g, were housed in pairs on a 12-hour/12-hour 
light/dark schedule (0700 h lights on), with access to food and water ad libitum.  
Animals were allowed to acclimate to the housing environment for seven days 
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before any experiments began.  Animals used in the microinjection studies were 
housed in pairs until the surgery and were singly housed after surgery. Housing 
procedures for the repeated social stress experiments are described below.  All 
animals were treated in accordance with the National Institutes of Health 
Guidelines on Laboratory Animal Use and Care and in accordance with the 
guidelines set by the university committee on use and care of animals at the 
University of Michigan. 
 
 
Repeated social stress 
 
 
To determine the regulation of FGF9 gene expression following stress, we used 
a repeated social stress paradigm consisting of two phases, a training phase 
lasting four days and a repeated stressor phase lasting ten days.  During both 
phases, Long-Evans male rats (400-450g) were housed with ovariectomized 
female rats to increase their territorial response and aggressive behavior.  During 
the daily 15-minute social stress episode, Long-Evans females were first 
removed from the resident cage and an intruder Sprague-Dawley rat (250-300g) 
was introduced.  The intruder was allowed to move freely throughout the cage 
until an intense physical episode occurred (1-5 minutes).  After an initial physical 
attack, intruders were placed in a protective wire mesh cage (30 x 15 x 15cm) 
and back into the residents’ home cage for the remainder of the 15-minute trial.  
This paradigm allowed for intense visual, auditory, and olfactory interactions 
emphasizing the psychosocial component of the stress while maintaining the 
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physical safety of the intruder rat (Miczek 1991; Kabbaj, Evans et al. 2004).  After 
the 15-minute social stress period, intruders were returned to their home cage 
and were singly housed.  The female Long-Evans rats were returned to the cage 
of the resident.  The intruders and residents were housed in different rooms 
throughout the entirety of the experiment. During the training phase, four days, 
Long-Evans residents (n=15) were trained to attack non-experimental Sprague-
Dawley intruders and were included when latency to attack was less than one 
minute.  Residents (n=2) that were not included in the experimental group, were 
used as novel resident targets in the social interaction test.  During the repeated 
stressor phase, ten days, intruders were placed in a cage with a novel resident 
every day for 15 minutes during the dark phase of the light cycle between 1900 h 
and 2200 h.  Control animals were placed in a novel cage and allowed to move 
freely for the 15-minute period.  Body weights were measured on Day 1 of the 
repeated social stress and on Day 10 following the last stress period. 
 
 
Social interaction test 
 
 
To determine whether repeated social stress caused any behavioral differences 
in the intruder rats compared to their non-stressed handled controls, we 
employed a novel measure of social interaction (SI) that was recently shown to 
identify social avoidance in mice susceptible to social defeat.  This social 
avoidance was long-lasting and reversible by chronic, but not acute, 
antidepressant treatment (Berton, McClung et al. 2006; Tsankova, Berton et al. 
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2006).  The modified social interaction testing arena consisted of a black 
Plexiglas open field (100 x 100cm) with boundaries marked for interaction zones 
and a target field.  The movement of the Sprague-Dawley intruder rat was 
recorded by a video tracking system (Noldus Ethovision).  The test consisted of 
two 5 minute trial periods on consecutive days.  Animals that were subjected to 
repeated social stress were assessed with no resident, novel Long-Evans rat, 
present on Day 1 and with the resident present on Day 2. On Day 1, the intruder 
was placed in the center of the testing field with no target.  The second trial, 24 
hours later, consisted of five minutes during which the intruder rat was placed in 
the center of the test field with a caged resident present.  The interaction ratio 
was calculated as 100 x (interaction time, target present)/ (interaction time, target 
absent).  Animals with a low social interaction ratio had increased social 
avoidance behavior.   
 
 
mRNA in situ hybridization   
 
 
In order to understand the regulation of key FGF ligands and receptors after our 
experimental procedures, tissue was collected 24 hours following the forced 
swim test for animals injected chronically with FGF9 or vehicle.  For animals 
subjected to repeated social stress, tissue was collected 24 hours after the 
second trial of the SI task.  All rats were sacrificed by rapid decapitation and their 
brains were removed, snap-frozen in isopentane, and stored at -80°C until 
sectioned.  Tissue was sectioned at -20°C at 10µm (n=5-6/group), sliced in 
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series throughout the hippocampus, mounted on Superfrost Plus slides (Fisher 
Scientific), and returned to -80°C until processed.  Sections were taken every 
200µm through the hippocampus and in situ hybridization methodology and 
analysis was performed as previously described in detail elsewhere (Kabbaj, 
Devine et al. 2000).  All in situ probes were synthesized in our laboratory and 
exposure times were experimentally determined for optimal signal and are as 
follows: FGF2 (7 days), FGF9 (14 days), and FGFR1 (7 days).  The rat mRNA 
sequences used for generating probes were complimentary to the following 
RefSeq database numbers: FGF2 (NM_019395, 716-994), FGF9 (NM_012952, 
661-880), FGFR1 (NM_024146, 320-977).   All cDNA segments were extracted 
(Qiaquick Gel Extraction kit, Qiagen, Valencia, CA), subcloned in Bluescript SK 
(Stratagene, La Jolla, CA) and confirmed by nucleotide sequencing.   The probes 
were labeled in a reaction mixture of 1µg of linearized plasmid, 1X transcription 
buffer (Epicentre Technologies, Madison, WI), 125µCi of 35S-labeled UTP, 
125µCi of 35-S labeled CTP, 150µM ATP and GTP, 12.5mM dithiothreitol, 1µl of 
RNAse inhibitor, and 1.5µl of T7 or T3 RNA polymerase.  Radioactive signals 
were quantified using computer-assisted optical densitometry software, Scion 
Image (Scio Corporation, Frederick, MD).  Integrated optical densities were 
determined by outlining a subfield (CA1, CA2, CA3, and dentate gyrus) of the 
hippocampus on each hemisphere and correcting for background plus 3.5x its 
SD. Only pixels with grey values exceeding the threshold were included in the 
analysis.  Data from multiple sections per animal were averaged resulting in a 





To determine whether FGF9 microinjections had an effect on affective behavior, 
we performed a dose-response analysis based on similar doses of FGF2 that 
were known to alter depression-like and anxiety-like behaviors in rats (Turner, 
2008; Perez, 2009).  Rats were anesthetized with isofluorane and were 
implanted with a guide cannula (22-gauge, Plastics One Inc., VA).  The cannula 
was placed in the left lateral ventricle (coordinates from bregma: AP -1.1; ML 
+1.3; DV -3.0) using a small-animal stereotaxic instrument.  The guide cannula 
was anchored to the skull using dental cement and was fitted with an obturator.  
After five days of recovery, rats were exposed to Day One of the forced swim test 
(FST) and received a microinjection immediately following the stressor using a 
28-gauge injector cannula extending 1.5mm below the tip of the guide.  The 
microinjection cannula was connected by PE-20 tubing to a Hamilton syringe 
mounted on a syringe pump (Harvard Apparatus, MA) and rats were 
microinjected with either recombinant human FGF9 (0.2ng, 2ng, 20ng, 200ng, or 
2000ng, i.c.v.) (Cell Sciences, MA) or the vehicle (artificial extracellular fluid 
(aECF), i.c.v) with 100µg/ml bovine serum albumin (Kuhn, Winkler et al. 1997; 
Cambon, Hansen et al. 2004).  The total volume injected was 8µl infused at a 
rate of 1µl /min in freely moving animals.  The injector was left in place for five 
minutes to allow for diffusion.  The rats were then tested 24 hours later on Day 
Two of the FST.  One week later, rats were counterbalanced and received 






In order to determine whether chronic administration had a strengthened or 
differential effect on behavior compared to acute injections, rats were implanted 
with cannulae as described above and were microinjected daily with FGF9 (20ng, 
i.c.v.) or vehicle (aECF, i.c.v.) for a total of 18 days.  All microinjections were 
administered between 0800 h and 1200 h.  Rats were tested in the EPM (Day 
14), for locomotor activity (Day 15), and in the FST (Day 17 and Day 18).  All 
behavioral testing was performed between 0800 h and 1300 h (Kelliher, Connor 






After 15 days of chronic microinjections of vehicle (aECF, i.c.v.) or FGF9 (20ng, 
i.c.v.), locomotor activity was tested to determine if the results seen on behavioral 
tasks were due to non-specific alterations in locomotor ability.  The rats were 
placed in a 43 x 21.5 x 25.5cm acrylic cage with stainless steel floor gridding.  
Horizontal and vertical locomotor activity was monitored every five minutes  for 
one hour by two panels of photocells that recorded beam breaks.  The horizontal 
and vertical components were added together and an average was found for 
each animal and group.  The locomotion-testing rig and motion-recording 
software were developed in-house at the University of Michigan.  All locomotor 
testing took place between 0800 h and 1200 h. 
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Forced swim test   
 
 
The FST has high predictive validity for antidepressant activity and animals 
display “despair” behavior as indicated by a decrease in escape behaviors, 
swimming and climbing (Lucki 1997).  We performed this behavioral measure to 
determine the effect of FGF9 on depression-like behavior.  Day One consists of a 
15 minute pre-test swim and Day Two is a five minute test swim which provides 
valuable information on the animals’ reaction to the second day of stress 
(Porsolt, Bertin et al. 1977; Porsolt, Deniel et al. 1979).  The Day One pre-test 
swim aids in the development of immobility during the subsequent Day Two test 
session and increases the sensitivity to antidepressants (Borsini, Lecci et al. 
1989).   
 
Animals were placed in cylinders filled with water at a depth at which the rats’ tail 
could not touch the bottom and a temperature of 25°C.  Immediately following the 
Day One pre-test, animals were dried, returned to their home cage, and injected 
with FGF9 (0.2ng, 2ng, 20ng, 200ng, or 2000ng, i.c.v.) or vehicle (aECF, i.c.v.).  
Water was changed between animals and all sessions were recorded from above 
by a video camera.  All FST swim sessions took place between 0900 h and  
1200 h. The videotaped behaviors were scored by an observer blind to the 
experimental conditions (Lucki 1997).  Swimming consisted of horizontal 
movement throughout the cylinder.  Climbing was defined by vertically-directed 
movement of forepaws against the wall of the cylinder.  Immobility was defined 
as floating or the minimal movement necessary to keep the head above water 
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level.  Percent total duration of swimming, climbing, and immobility episodes was 




Elevated plus-maze   
 
 
The EPM was used to test the anxiety-like behavior of the rat by using their 
natural aversion to high, open spaces.  The maze consists of black Plexiglas with 
four elevated arms (70cm from the floor, 45cm long, and 12cm wide).  The EPM 
has two arms enclosed by 45cm-high wall and two open arms arranged in the 
shape of a cross.  At the intersection of the four arms of the maze, a 12 x 12cm 
square platform allowed access to all four arms.  During the five minute test 
period, the room is dimly lit (~40 lux), and behavior is monitored using a 
computerized video tracking system (Noldus Ethovision).  At the start of the five 
minute test, the rat was placed in the center square platform facing a closed arm.  
The tracking system recorded the latency to enter the open arm, the amount of 
time spent in arms, and the time spent in the center square.  After every animal, 
the testing apparatus was wiped down with 30% ethanol. Animals that spent a 
greater percentage of time in the closed arms were considered more anxious 
while, conversely, animals that spent a greater percentage of time exploring the 




Statistical Analyses   
 
 
FGF9 microinjection behavioral studies were analyzed by ANOVAs followed by 
Fisher’s least significant difference post hoc analysis and remaining studies were 
analyzed by a Student’s t-test with all data presented as mean +/- standard error 






Repeated social stress increased social avoidance behavior and increased 
FGF9 gene expression   
 
 
Repeated social stress has been shown to induce a variety of behavioral deficits 
similar to those seen in human depression (Blanchard, Spencer et al. 1995; 
Rygula, Abumaria et al. 2005).  It is also known that FGF2 and FGFR1 were 
decreased following an acute social defeat paradigm (Turner, Calvo et al. 2008).  
Therefore, we tested whether FGF9 expression was increased after repeated 
social stress, consistent with expression data seen in human post-mortem tissue.   
Rats subjected to the repeated social stress paradigm (Figure 3-1A) showed 
significantly increased change in percent body weight, animals that were 
repeatedly stressed did not gain weight at the same rate as handled controls 
(t(22) = 5.8, p < 0.001; Figure 3-1B). Additionally, repeatedly stressed animals 
showed increased social avoidance behavior (Figure 3-1D) on the social 
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interaction test (t(17) = 2.5, p < 0.03; Figure 3-1C) compared to handled controls.  
There were no significant differences in the FST (data not shown). 
The brains of the animals subjected to repeated social stress were harvested and 
analyzed for FGF9 mRNA transcripts.  There was an increase in hippocampal 
FGF9 mRNA expression following repeated social stress compared to handled 
controls.  This increase occurred through multiple hippocampal subregions: CA1, 
CA2, CA3, and DG (t(8) = 2.46, p < 0.04, t(8) = 3.41, p < 0.01, t(8) = 3.12, p < 
0.02, t(8) = 3.15, p < 0.02, respectively; Figure 3-2A and 3-2B). 
 
 
An acute microinjection of FGF9 altered EPM and FST activity in a dose-
dependent manner  
 
 
FGF9 mRNA expression was upregulated in a number of brain regions in post-
mortem tissue of patients diagnosed with MDD (Evans, 2004), and chronic FGF2 
administration has antidepressant and anxiolytic effects on adult rats (Turner 
2008).  Thus we decided to test the hypothesis that FGF9 had an opposing effect 
on affective behavior.  We first began by administering a dose-response curve 
with median doses similar to those in which FGF2 caused behavioral responses 
in both the FST and the light dark box (Turner, Gula et al. 2008; Perez, Clinton et 
al. 2009).   
 
There was an overall anxiolytic effect of acute FGF9 administration in the 
elevated plus-maze with increased percent total duration spent in the open arms 
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and decreased percent total duration in the closed arms (F(5,58) = 4.3, p < 0.003; 
F(5,58) = 3.3, p < 0.02; Figure 3-3A).  Post hoc comparisons of each FGF9 dose 
with vehicle indicated that FGF9 showed an inverted U-shape dose-response 
curve with a moderate dose (p < 0.01 for 20ng) increasing percent time spent in 
the open arms and decreasing percent time spent in the closed arms (p < 0.05 
for 20ng FGF9) compared to vehicle controls.  
 
Similarly, there was a main effect of FGF9 administration on performance in the 
FST.  There was an overall depression-like effect of FGF9 administration as 
evidenced by a decrease in the percent total duration spent swimming and a 
significant increase in percent total duration spent immobile (F(5,66) = 3.1, p < 
0.02, F(5,66) = 5.1, p < 0.002, respectively; Figure 3-3B) compared to vehicle 
controls.  Post-hoc analysis for dose effects showed that both a 20ng and 200ng 
microinjection of FGF9 increased depression-like behavior both by decreasing 
percent time spent swimming (p < 0.004 for both 20ng and 200ng) and 
increasing percent time spent immobile (p < 0.002 for both 20ng and 200ng) 
compared to vehicle controls.   
 
 
Chronic FGF9 microinjections increased anxiety-like behavior and 
increased depression-like behavior 
 
 
As described above, acute FGF9 microinjections resulted in alterations in 
affective behavior.  It is known that an acute injection of an antidepressant  
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increased anxiety while chronic antidepressant injections decreased anxiety 
(Bagdy, Graf et al. 2001; Belzung, Le Guisquet et al. 2001; Burghardt, Bush et al. 
2007). To that end, we tested whether chronic FGF9 administration continues to 
have the same effects on both anxiety-like and depression-like behavior.  We 
administered the lowest dose (20ng FGF9) that had an acute behavioral effect on 
both the EPM and the FST. 
  
Our results indicated that while chronic FGF9 administration continued to 
increase depression-like behavior, the long-term effects on anxiety-like behavior 
are reversed.  The chronic dose of FGF9 increased anxiety-like behavior on the 
EPM with FGF9-microinjected animals having a significantly decreased percent 
total duration spent in the open arms of the EPM (F(1,16) = 8.1, p < 0.05;  
Figure 3-4A) compared to vehicle controls.  Consistent with the acute 
microinjections, there was a decrease in percent total duration spent swimming 
and an increase in the percent total duration spent immobile (F(1,14) = 7.3, p < 
0.05, F(1,14) = 6.6, p < 0.05, respectively; Figure 3-4B) in animals injected with 
FGF9 compared to vehicle controls.   
 
 
Neither acute nor chronic FGF9 microinjections altered locomotor activity 
during the behavioral test period 
 
 
In order to rule out non-specific effects of FGF9 on locomotor behavior that could 
influence activity in the FST or EPM, locomotor activity was monitored 24 hours 
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after the acute or chronic microinjections (20ng, i.c.v.).  The testing took place 
during the same time that the FST testing took place (0900 h to 1000 h) in a 
separate set of animals.  The acute microinjections resulted in no change in 
locomotor activity 15 minutes post-injection as measured by the total distance 
traveled in the EPM (t(16) = 0.99, p = 0.33; Figure 3-3C).  The acute 
microinjection caused no change in locomotor activity 24 hours after the injection 
as measured by beam breaks in a locomotion chamber (t(8) = .03, p = 0.98; 
Figure 3-3D). Chronic microinjections of FGF9 also had no effect on locomotor 
activity during the period in which the behavioral testing took place (t(17) = 0.13, 
p = 0.902; Figure 3-2C).  
 
 
Chronic FGF9 microinjections decreased FGFR1 gene expression in the 
dentate gyrus of the hippocampus 
 
 
To assess whether the depression-like and anxiety-like effects of chronic FGF9 
administration were associated with corresponding FGF family mRNA expression 
changes in the hippocampus, we tested whether there were changes in FGF2, 
FGFR1, or FGF9 mRNA transcripts in four regions of the hippocampus (CA1, 
CA2, CA3, and dentate gyrus).  Although chronic FGF9 had no effect on FGF2 or 
FGF9 gene expression in the hippocampus (data not shown), chronic FGF9 led 
to a dentate gyrus-specific decrease in FGFR1 mRNA expression (t(8) = -2.45, p 






These studies show for the first time that FGF9 altered both anxiety-like and 
depression-like behavior and is itself modulated by social stress.  Specifically, we 
found that: (1) chronic social stress increased social avoidance behavior in 
intruder rats and increased the hippocampal expression of FGF9 mRNA, (2) 
acute administration of FGF9 (multiple doses, i.c.v.) decreased anxiety-like 
behavior and increased depression-like behavior in a dose-dependent manner, 
(3) chronic administration of FGF9  (20ng, i.c.v.) increased anxiety-like behavior, 
reversing the result seen acutely, and increased depression-like behavior, and 
(4) chronic administration of FGF9 (20ng, i.c.v.) decreased the expression of 
hippocampal FGFR1 specifically in the dentate gyrus subfield. These findings 
support the hypothesis that excess exogenous FGF9 protein or endogenous 
FGF9 gene expression may have negative effects on anxiety-like and 
depression-like behavior.  It is important to note that FGF9 is acting as an 
endogenous physiological antagonist to FGF2 as evidenced by opposing 
behavioral and gene expression data.  This data suggests that FGF9 may be a 
potential therapeutic target for peptide inhibition and treatment of MDD. 
 
Repeated social stress is critical to survival of most individuals, and animals who 
face these conditions are likely to exhibit signs of stress (Kollack-Walker, Watson 
et al. 1997).  In humans, repeated social defeat encounters increase rates of 
incidence of psychiatric disorders, disease, and even death (Blanchard, Sakai et 
al. 1993; Kaplan, Asnis et al. 1995; Lemieux and Coe 1995; Gil-Rivas, Fiorentine 
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et al. 1996).	  	  In this experiment we observed a significant increase in percent 
change of body weight and increased social avoidance behavior compared to 
handled controls.  This evidence supported that increases in FGF9 gene 
expression are correlated to behavioral and physiological measures of stress 
response. As gene expression of FGF2 and FGF9 were dysregulated in MDD in 
opposing directions (Evans, Choudary et al. 2004), expression was also altered 
in opposing directions after acute social defeat or repeated social stress.  The 
increase in FGF9 gene expression after repeated social stress is consistent with 
human findings in which FGF9 is increased in MDD.  FGF9 may provide a 
relevant biomarker for mood dysregulation. 	  
 
While we have no direct evidence of FGF2/FGF9 regulation, we know that FGF2 
and FGF9 have opposing actions on GFAP-positive astrocytes. FGF2 increased 
the presence of astrocytes in the hippocampus and cortex (Perez, 2008; Reuss, 
2003) and FGF9 decreased astrocyte differentiation in adult neural progenitor 
cells (Lum, 2009).  While differences in astrocytic differentiation could have an 
effect on neural differentiation, it is also possible that an FGF9-mediated 
decrease in astrocytes, which are the primary synthesis sites of FGF2, could lead 
to a decrease in FGF2 synthesis. 
 
   
While we have shown that FGF2 has anxiolytic and antidepressant-like effects in 
vivo (Turner, Gula et al. 2008; Perez, Clinton et al. 2009), this is the first study to 
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show a direct effect of FGF9 on anxiety-like and depression-like behavior.  We 
show that FGF9 treatment is dose-dependent with a U-shape dose-response 
curve (Calabrese and Baldwin 2003).  This pharmacological response is common 
in ligand-receptor activation in which ligands can be partial agonists at lower to 
moderate doses and antagonists at high doses.  Although it was unexpected that 
FGF9 would be an acute anxiolytic, it was hypothesized that FGF9 would have a 
depression-like effect in microinjected animals.  However, it is not uncommon for 
antidepressant treatments to first cause an anxiogenic response and chronically 
result in anxiolytic behavioral effects (Bagdy, Graf et al. 2001; Belzung, Le 
Guisquet et al. 2001; Burghardt, Bush et al. 2007).  This reversal in effect on 
anxiety mirrors the results seen with acute and chronic FGF2 microinjection.  
Acute FGF2 is anxiogenic, while chronic FGF9 is anxiolytic .  
 
It is possible that an initial acute anxiolytic response can result in chronic 
anxiogenic behavior.  This reversal in effect on anxiety, from anxiolytic to 
anxiogenic, was seen after chronic administration and implicates FGF9 in the 
increase in anxiety-like behavior.  The chronic injection of FGF9 (20ng, i.c.v) 
continued to increase depression-like behavior in the FST.  Since there is 
significant co-morbidity between clinical anxiety and depression, it is likely that 
there are conserved mechanisms for behavioral modulation (Gorwood 2004).  As 
an exogenous injection of FGF9 is responsible for a negative effect on both 
anxiety and depression, it is a logical therapeutic target for small-molecule 
inhibition for the treatment of MDD.  However, further studies into the regulation 
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of FGF9 would need to be done to determine the exact mechanisms by which it 
alters affective behavior in vivo. 
 
In this study, we show that chronic administration of exogenous FGF9 led to a 
decrease in FGFR1 gene expression. In contrast, we have shown that chronic 
administration of FGF2 increased FGFR1 gene expression (Turner, Gula et al. 
2008).  Interestingly, both of the changes in gene expression were selective to 
the dentate gyrus of the hippocampus.  Other research has shown that sub-
region specific knockout of another growth factor, brain-derived neurotrophic 
factor (BDNF), in the dentate gyrus, specifically attenuated antidepressant 
activity compared to CA1-specific BNDF knockouts (Adachi, Barrot et al. 2008).  
The preferential decrease of FGFR1 in dentate gyrus of the hippocampus may 
lead to decreased FGF2 signaling activity in this region since the FGF2 ligand 
primarily activates FGFR1 (Ornitz, Xu et al. 1996). 
 
 
Although FGF9 can induce neurogenesis in adult neural progenitor cells, it 
mainly increased the number of early neural progenitors (Lum, Turbic et al. 
2009).  FGF9 also enhanced long-term survival of spinal motor neurons, 
bulbospinal neurons, and the basal forebrain cholinergic neurons in vitro (Kanda, 
Iwasaki et al. 1999; Pataky, Borisoff et al. 2000).  This evidence suggests a 
maintenance role for FGF9 in which it slows the process of neuronal 
differentiation.  In contrast, FGF2 causes a distinct induction of precursor cells in 
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the CNS (Vescovi, Reynolds et al. 1993; Shihabuddin, Ray et al. 1997) and 
promotes neurogenesis in vivo in developing (Raballo, Rhee et al. 2000) and 
adult rats (Yoshimura, Takagi et al. 2001).   
 
Classical antidepressants induce FGF2 expression (Mallei, Shi et al. 2002)  and 
increase neurogenesis (Malberg et al, 2000).  Recent studies show conflicting 
evidence on whether neurogenesis is necessary for antidepressant action 
(Sahay and Hen, 2008; David et al, 2009).  However, there is a prevailing 
neurotrophic hypothesis which is supported by numerous studies in which the 
decrease of growth factors increases vulnerability to depression (Duman and 
Monteggia 2006) while induction of growth factors might be an underlying 
mechanism of antidepressant action (Berton and Nestler, 2006; Warner-Schmidt 
and Duman 2008).  As FGF9 appears to be acting as a physiological antagonist 
to FGF2, it may be interfering with the induction of FGF2-mediated cell survival 
that is correlated with antidepressant activity (Perez, Clinton et al. 2009). 
 
The following evidence supports that FGF9 may be a physiological antagonist to 
FGF2: (1) repeated social stress upregulated FGF9 gene expression and in 
contrast social defeat decreased FGF2 gene expression (Turner, Calvo et al. 
2008), (2) an acute FGF9 microinjection was anxiolytic and increased 
depression-like behavior and conversely an acute FGF2 microinjection was 
anxiogenic and antidepressant-like (Perez, unpublished data), (3) chronic FGF9 
microinjections were anxiogenic and increased depression-like behavior while 
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chronic FGF2 microinjections were anxiolytic and antidepressant-like (Turner, 
Gula et al. 2008), and (4) chronic FGF9 microinjections decreased hippocampal 
FGFR1 expression while chronic FGF2 microinjections increased hippocampal 
FGFR1 gene expression (Turner, Gula et al. 2008).  These observations support 
the hypothesis that FGF9 is acting as a naturally occurring physiological 
antagonist to FGF2.  Overall, increased FGF9 is correlated with both increased 
stress and negative behavioral consequences.  Thus, FGF9 appears to be an 
ideal candidate for targeted inhibition and a novel therapeutic target for the 
treatment of mood disorders. 
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Results Figures 
Figure 3-1: Repeated social stress increased percent change in body 














A) Timeline of the repeated social stress experiment.  B) Rats subjected to 
repeated social stress showed increased social avoidance as evidenced by a 
decrease in the social interaction ratio in the social interaction task compared to 





Figure 3-1 (continued):  Repeated social stress increased percent change 














C) Scaled diagram of the interaction arena (100cm X 100cm) including the 
interaction zone and target area. D) Rats subjected to repeated social stress had 
a significant percent change in body weight indicative of increased stress 
compared to vehicle controls; ***p < 0.001 (n= 8-10 animals per group).  
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A) Representative mRNA in situ hybridization images from handled controls (left) 
and repeated social stress animals (right). B) Repeated social stress significantly 
increased FGF9 gene expression in hippocampal subregions: CA1, CA2, CA3, 
and dentate gyrus;*p < 0.05, **p < 0.01 (n= 5 animals per group). 
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Figure 3-3: Acute FGF9 microinjections decreased anxiety-like behavior 







A) An acute microinjection of FGF9 decreased anxiety-like behavior in an 
inverted-U dose-response curve as shown by a decrease in the percent time 
spent on the open arm compared to vehicle controls;  **p < 0.01, *p < 0.05 (n= 8-
10 animals per group). B) An acute microinjection of FGF9 increased depression-
like behavior in a dose-dependent curve as shown by the decrease in percent 
time spent swimming and increased percent time immobile in the FST compared 
to vehicle controls (n= 8-10 animals per group). 
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Figure 3-3 (continued):  Acute FGF9 microinjections decreased anxiety-like 










C) Acute microinjections of FGF9 have no effect on locomotor activity 15 minutes 
following the microinjection (n= 8-10 animals per group).  D) Acute 
microinjections of FGF9 have no effect on locomotor activity 24 hours following 
the microinjection (n= 5 animals per group). 
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Figure 3-4: Chronic FGF9 microinjections increased anxiety-like behavior 






A) Chronic microinjections increased anxiety-like behavior as evidenced by a 
decrease in the percent time spent on the open arm compared to vehicle 
controls; *p < 0.05 (n= 8-10 animals per group).  B) Chronic microinjections 
increased depression-like behavior as shown by decreased percent time spent 
swimming and increased percent time spent immobile in the FST compared to 
vehicle controls;  *p < 0.05 (n= 8-10 animals per group). 
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Figure 3-4 (continued): Chronic FGF9 microinjections increased anxiety-





C) Chronic microinjections of FGF9 had no effect on locomotor activity 24 hours 
following administration (n=10-12 animals per group). 
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Figure 3-5: Chronic FGF9 microinjections decreased hippocampal FGFR1 
gene expression. 
 
A.            






A) Representative mRNA in situ hybridization images from vehicle controls (left) 
and chronic FGF9 microinjected animals (right).  B) Chronic microinjections for 
18 days significantly decreased FGFR1 gene expression in the hippocampal 
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Circadian variations of the fibroblast growth factor family  






In the present study, we examined the circadian patterns of fibroblast growth 
factor-2 (FGF2), fibroblast growth factor-9 (FGF9), and fibroblast growth factor 
receptor-1 (FGFR1) mRNA expression in the adult rodent hippocampus.  
Animals were sacrificed at 4-hour intervals throughout a 24-hour light-dark cycle, 
and the gene expression of FGF2, FGF9, and FGFR1 was evaluated by mRNA 
in situ hybridization.  We observed a significant circadian rhythm in FGF2 
expression, with a peak at 1600 h (two hours before lights off) and a trough at 
0800 h (one hour after lights on).  In contrast, FGFR1 mRNA expression peaked 
at 2400 h and was lowest at 1200 h in a pattern lagging the expression profile of 
FGF2.  FGF9 gene expression showed no significant circadian variation.  We 
observed that the peak in FGF2 expression coincided with the peak in circulating 
plasma corticosterone in the same experimental animals.  In addition to 
investigating the endogenous fluctuation of FGF2, FGF9, and FGFR1 mRNA 
expression, we also tested whether a single microinjection of FGF2, administered 
between 0700 h and 0900 h, could alter circadian locomotor activity.  The FGF2 
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microinjection (200ng, i.c.v.) caused an increase in the dark-phase (active 
period) locomotor activity compared to vehicle-injected controls (aECF, i.c.v.).  
These findings provide the first evidence that, in the absence of any experimental 
manipulation, the expression of FGF2 and FGFR1 undergo circadian oscillations.  
These fluctuations in mRNA expression could be linked to circulating 





The discovery of the dysregulation of the FGF system gene expression in post-
mortem tissue of individuals diagnosed with major depressive disorder (MDD) 
(Evans, Choudary et al. 2004; Evans, Choudary et al. 2004b; Akil, Evans et al. 
2008) has led to an increased interest in the role of this growth factor family in 
brain regions associated with mood disorders.  In MDD, FGF2 gene expression 
was downregulated while FGF9 expression was upregulated in cortical and 
subcortical regions.  FGF receptors were also downregulated (Evans, Choudary 
et al. 2004; Sibille, Arango et al. 2004; Evans, Choudary et al. 2004b; Gaughran, 
Payne et al. 2006). It is known that FGF2 expression is increased by 
antidepressants (Mallei, Shi et al. 2002), and FGF2 and FGFR1 expression are 
decreased following acute social defeat (Turner, Calvo et al. 2008).  Chronic 
administration of FGF2 decreased anxiety-like behavior (Perez, Clinton et al. 
2009) and increased antidepressant-like behavior (Turner, Gula et al. 2008).  
Chronic FGF9 microinjections increased anxiety-like behavior and increased 
depression-like behavior in adult rodents (Inui, unpublished data).  Changes in 
gene expression of FGF2, FGF9, and FGFR1 as well as exogenous 
administration of FGF2 and FGF9 can be correlated to behavioral consequences.  
It is important to consider the endogenous circadian fluctuation of FGF2, FGF9, 
and FGFR1 gene expression to better understand how their dysregulation may 
alter behavior.  The FGF family may play an important role in both circadian 
activity and environmental responsivity. 
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FGF2 has an established role in transcriptional regulation, cellular proliferation 
and neurogenesis in the adult rat (Kuhn, Winkler et al. 1997; Palmer, Markakis et 
al. 1999; Jin, Sun et al. 2003; Zhao, Li et al. 2007).  FGF2 has moderate levels of 
expression in the rat hippocampus and its actions are primarily mediated by 
fibroblast growth factor receptor-1 (FGFR1).  In contrast to FGF2, FGFR1 is  
highly expressed in the rat hippocampus (Gonzalez, Berry et al. 1995).   
Furthermore, the activation of FGFR1, leads to MAPK and PLCγ activation which 
alter downstream transcriptional regulation and cytoskeletal organization (Dailey, 
Ambrosetti et al. 2005).  The activation of these two pathways, through FGFR1 
signaling, has recently been implicated in the maintenance and self-renewal of 
adult neural stem cells (Ma, Ponnusamy et al. 2009).  FGF9 is also expressed in 
the rat hippocampus (Tagashira, Ozaki et al. 1995; Todo, Kondo et al. 1998) and 
is thought to support neuronal survival through an autocrine/paracrine system 
(Kanda, Iwasaki et al. 1999). FGF9 primarily activates fibroblast growth factor 
receptor-3 (FGFR3) (Reuss and von Bohlen und Halbach 2003), but it may play 
a role as a physiological antagonist to FGF2 (Inui, unpublished data). 
 
The discovery of the dysregulation of the FGF system gene expression in post-
mortem tissue of individuals diagnosed with major depressive disorder (MDD) 
(Evans, Choudary et al. 2004; Evans, Choudary et al. 2004b; Akil, Evans et al. 
2008) has led to an increased interest in the role of this growth factor family in 
brain regions associated with mood disorders.  In MDD, FGF2 gene expression 
was downregulated while FGF9 expression was upregulated in cortical and 
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subcortical regions.  FGF receptors were also downregulated (Evans, Choudary 
et al. 2004; Sibille, Arango et al. 2004; Evans, Choudary et al. 2004b; Gaughran, 
Payne et al. 2006). It is known that FGF2 expression is increased by 
antidepressants (Mallei, Shi et al. 2002), and FGF2 and FGFR1 expression are 
decreased following acute social defeat (Turner, Calvo et al. 2008).  Chronic 
administration of FGF2 decreased anxiety-like behavior (Perez, Clinton et al. 
2009) and increased antidepressant-like behavior (Turner, Gula et al. 2008).  
Chronic FGF9 microinjections increased anxiety-like behavior and increased 
depression-like behavior in adult rodents (Inui, unpublished data).  Changes in 
expression of FGF2 and FGFR1 as well as exogenous administration of FGF2 
can be linked to behavioral consequences.  It is important to consider the 
endogenous circadian fluctuation of FGF2 and FGFR1 gene expression to better 
understand how their dysregulation may alter behavior. 
 
Since FGF2 supports enhanced cellular production and dendritic growth in the 
dentate granule cell layer, it may be valuable to consider the relationship of its 
circadian variations in relationship to those of cell proliferation and synaptic 
plasticity (Rai, Hattiangady et al. 2007).  Adult neurogenesis, cell proliferation, 
and alteration of hippocampal architecture have been implicated in functional 
plasticity of neural circuits at the cellular, network, and systems level (Lledo, 
Alonso et al. 2006).  The proliferation and maturation of new neurons and along 
with increased spine density and arborization in the dentate gyrus have been 
shown to play a role in certain hippocampal-dependent cognitive abilities 
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(Lemaire, Aurousseau et al. 1999; Drapeau, Mayo et al. 2003; Leuner, Mendolia-
Loffredo et al. 2004).   
 
For decades, we have known of a strong association between depression and 
sleep dysregulation (Wirz-Justice 2006).  Alterations of circadian rhythms in MDD 
were first described over 40 years ago (Fullerton, Wenzel et al. 1968; Foster and 
Kupfer 1975; Claghorn, Mathew et al. 1981; Van Cauter and Turek 1986; 
Germain and Kupfer 2008), and many individuals with MDD complain of sleep-
wake cycle abnormalties (Haynes, McQuaid et al. 2006; Monteleone and Maj 
2008) .  These individuals often have an overall increase in cortisol secretion and 
a phase advance of the cortisol circadian rhythm (Linkowski, Mendlewicz et al. 
1985; Linkowski, Van Cauter et al. 1985).  Primary disruption of the sleep-wake 
cycle could lead to insomnia that may facilitate or exacerbate the depressed 
state. Thus, alterations of the biological clock at the molecular level could lead to 
neurobiological dysfunction, such as MDD.  Similarly, fluctuations in FGF 
expression may precipitate some of the activity-related changes underlying mood 
disorders. 
 
In the present study, we examined the possibility that FGF2, FGF9, and FGFR1 
undergo circadian oscillation in the absence of experimental manipulation.  Basal 
expression was quantified at four-hour intervals during the dark-cycle (active 
period) and light-cycle (inactive period).  In order to investigate the endogenous 
fluctuations of FGF2, FGF9, and FGFR1 gene expression, we used quantitative 
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mRNA in situ hybridization.  We also recorded the light-dark cycle oscillation of 
circulating plasma corticosterone in the same group of animals.  To determine if 
exogenous administration of FGFs could alter the circadian activity cycle of adult 
rats, we evaluated the locomotor activity of adult rodents for 36 hours following 
an acute microinjection of FGF2 (200ng, i.c.v.). 
 
 






All male Sprague-Dawley rats (Charles river Laboratories, Inc., Wilmington, MA), 
weighing 250g to 300g, were housed in pairs on a 12 hour  light, 12 hour dark 
cycle with lights on at 0700 h .  Food and water were available ad libitum and the 
animals were allowed to acclimate to the housing conditions for one week before 
experiments began. All animals were treated in accordance with the National 
Institutes of Health Guidelines on Laboratory Animal Use and Care and in 
accordance with the guidelines set by the university committee on use and care 






For the determination of circadian patterns of FGF2, FGF9, and FGFR1 mRNA 
as well as circulating cortiscosterone levels, 36 animals (6 rats/group) were used.  
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Animals were sacrificed by rapid decapitation at four-hour intervals for 24 hours 
starting at 0800 h.  Trunk blood was collected into EDTA-coated tubes and kept 
on ice until centrifugation (1000g, 10 minutes at 4 °C).   Plasma was separated, 
frozen on dry ice, and stored at -80°C. Plasma corticosterone was measured 
using a commercially available radioimmunoassay kit (MP Biomedicals, Solon, 
OH) according to package instructions. All rats were sacrificed by rapid 
decapitation and their brains were removed, snap-frozen in isopentane, and 
stored at -80°C until sectioned.  Tissue was sectioned at -20°C at 10µm 
(n=6/group), sliced in series throughout the hippocampus, mounted on Superfrost 
Plus slides (Fisher Scientific), and returned to -80°C until processed.  All animals 
at each time point were sacrificed within 45 minutes and safe lights were used 
during the dark cycle to avoid exposure to light that might alter circadian rhythm. 
 
 
mRNA in situ Hybridization 
 
 
Tissue sections were taken every 200µm through the rostral hippocampus and in 
situ hybridization methodology and analysis was performed as previously 
described in detail elsewhere (Kabbaj, Devine et al. 2000).  All in situ probes 
were synthesized in our laboratory and exposure times were experimentally 
determined for optimal signal and are as follows: FGF2 (7 days), FGF9 (14 days) 
and FGFR1 (7 days).  The rat mRNA sequences used for generating probes 
complimentary to the following RefSeq database numbers: FGF2 (NM_019395, 
716-994), FGF9 (NM_012952, 661-880), and FGFR1 (NM_024146, 320-977).   
 133 
All cDNA segments were extracted (Qiaquick Gel Extraction kit, Qiagen, 
Valencia, CA), subcloned in Bluescript SK (Stratagene, La Jolla, CA) and 
confirmed by nucleotide sequencing.   The probes were labeled in a reaction 
mixture of 1µg of linearized plasmid, 1X transcription buffer (Epicentre 
Technologies, Madison, WI), 125µCi of 35S-labeled UTP, 125µCi of 35-S labeled 
CTP, 150µM ATP and GTP, 12.5mM dithiothreitol, 1µl of RNAse inhibitor, and 






Radioactive signals were quantified using computer-assisted optical densitometry 
software, Scion Image (Scio Corporation, Frederick, MD).  Integrated optical 
densities were determined by outlining a subfield (CA1, CA2, CA3, and DG) of 
the hippocampus on each hemisphere and correcting for background plus 3.5x 
its standard deviation. Only pixels with grey values exceeding the threshold were 
included in the analysis.  Data from multiple sections (10-12 hippocampal 
measurements per animal) were averaged resulting in a mean for each animal 







Rats were anesthetized with isofluorane and were implanted with a guide 
cannula (22-gauge, Plastics One Inc., VA).  The cannula was placed in the left 
lateral ventricle (coordinates from bregma: AP -1.1; ML +1.3; DV -3.0) using a 
small-animal stereotaxic instrument.  The guide cannula was anchored to the 
skull using dental cement and was fitted with an obturator.  After five days of 
recovery, rats received a microinjection, between 0700 h and 0900 h, using a 28-
gauge injector cannula extending 1.5mm below the tip of the guide.  The 
microinjection cannula was connected by PE-20 tubing to a Hamilton syringe 
mounted on a syringe pump (Harvard Apparatus, MA) and rats were 
microinjected with either recombinant human FGF2 (200ng, i.c.v.) or the vehicle 
(artificial extracellular fluid (aECF), i.c.v) with 100µg/ml bovine serum albumin 
(Kuhn, Winkler et al. 1997; Cambon, Hansen et al. 2004; Turner, Gula et al. 
2008).  The total volume injected was 8µl infused at a rate of 1µl /min in freely 
moving animals.  The injector was left in place for five minutes to allow for 
diffusion.  The rats were placed into locomotion chambers for monitoring 






After an acute microinjection of vehicle (aECF, i.c.v.) or FGF2 (200ng, i.c.v.), 
locomotor activity was tested to determine whether exogenous FGF2 caused an 
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alteration in locomotion over a 36-hour period.  The rats were placed in a 43 x 
21.5 x 25.5cm acrylic cage with normal cage bedding and allowed access to food 
and water ad libitum.  Horizontal locomotor activity was monitored every 60 
minutes for 36 hours. The results exclude the highly variable locomotor activity 
during the acclimation to the locomotor box.  The horizontal activity was 
averaged for each group.  The locomotion-testing rig and motion-recording 






All mRNA in situ hybridization results were analyzed by a general linear model 
for repeated measures over all hippocampal subregions.  An ANOVA was 
performed to determine the overall hippocampal FGF2, FGF9, and FGFR1 gene 
expression profiles and corticosterone secretion with Fisher’s least statistical 
difference (LSD) between peak and trough.  An ANOVA was performed on the 
locomotor activity data with Fisher’s LSD determined between FGF2 and vehicle-
injected animals. Data are expressed as mean +/- standard error of the mean.  







Circadian variation of FGF2 mRNA in the hippocampus 
 
 
The largest difference in basal FGF2 mRNA expression was noted between the 
expression trough at 0800 h and expression peak 1600 h (Figure 4-1A).  Analysis 
of FGF2 mRNA expression data revealed a circadian rhythm with a single peak 
in mRNA expression (Figure 4-1B).  Statistical analysis by one-way ANOVA 
indicated significant effects of time of day on FGF2 mRNA expression in the 
hippocampus averaged over all four regions (F(5,26)= 3.0, p < 0.03).  The average 
hippocampal trough value of FGF2 expression occurred at 0800 h, one hour after 
lights on, after which levels of FGF2 mRNA rapidly peaked at 1600 h (p < 0.004 
vs. 0800 h), three hours before lights off.  All four regions (DG, CA1, CA2, CA3) 
quantified had similar expression patterns over the 24-hour light-dark cycle and 
contributed to the overall expression profile (F(5,26) = 3.4, p < 0.001; Figure 4-1C). 
 
 
Circadian variation of FGFR1 mRNA in the hippocampus 
 
 
The largest difference in FGFR1 mRNA expression was noted between trough 
expression at 1200 h and peak expression at 2400 h (Figure 4-2A).  Statistical 
analysis by one-way ANOVA indicated significant effects of time of day on 
FGFR1 mRNA expression in the hippocampus.  The peak value of FGFR1 
expression occurred at 2400 h, five hours after lights off, after which average 
hippocampal FGFR1 expression decreased rapidly with a through at 1200 h, five 
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hours after lights on (p < 0.006 vs. 2400 h; Figure 4-2B).  Expression increased 
between 1200 h and 1600 h but still remained significantly lower than peak 
FGFR1 expression (p < 0.04 vs. 2400 h).  CA3 had the most clear pattern of 
expression whereas CA2 had the least clear pattern  (F(5,27)= 3.0, p < 0.03; 
Figure 4-2C).   
 
 
FGF9 mRNA expression showed no circadian variation in the hippocampus 
 
  
Statistical analysis by one-way ANOVA indicated no significant effects of time of 
day on FGF9 mRNA expression in the hippocampus (Figure 4-3A).  While FGF9 
expression does not fluctuate over a 24-h light-dark cycle, the ratio of FGF9 to 
FGF2 is altered by the variation of FGF2 expression (Figure 4-3B). 
 
 
The peak in FGF2 gene expression coincided with a rise in circulating 
plasma corticosterone levels 
 
 
Circulating corticosterone concentrations exhibited a significant circadian rhythm  
in rats housed under 12-hour light, 12-hour dark illumination conditions with food 
available ad libitum (F(5,35) = 7.6, p < 0.001; Figure 4-4).  Plasma corticosterone 
levels were low in the morning (from 0800 h-1200 h), ranging from 21.9 - 
41.7pg/ml.  Corticosterone levels exhibited an increase from trough expression to 
reach a peak at the light/dark transition phase, 1600 h (187.6 +/- 16.6 pg/ml, p < 
0.001 vs. 0800 h) and remained significantly higher than trough expression at  
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2000 h (p < 0.002 vs 0800 h).  Subsequently corticosterone levels declined to 
113.7 +/- 41.5 pg/ml (p < 0.02 vs. 0800h) before returning to trough expression, 
21.9 +/- 9.6 pg/ml,at 0800 h (Figure 4-4). 
 
 
A single FGF2 microinjection increased locomotor activity during the dark-
cycle (active period) 
 
An ANOVA showed there was a significant interaction between treatment and 
locomotor activity (F(1,16) = 2.7, p < 0.05; Figure 4-5).  In response to a single 
microinjection of FGF2 (200ng, i.c.v.), administered between 0700 h and 0900 h, 
rats showed a significant increase in locomotor activity compared to vehicle-
injected (aECF, i.c.v.) controls during the dark-cycle (active period) and were 
significantly different at 1900 h, 2000 h, 2200 h, 2300 h and 0300 h (p < 0.03, p < 
0.02, p < 0.002, p < 0.04 and p < 0.05, respectively; Figure 4-5). There were 
significant differences in activity during the first dark-cycle, however, locomotor 
changes did not persist into the next cycle. There were no significant differences 






The results of this study provide the first evidence that the gene expression of the 
FGF family exhibited circadian oscillations in the absence of experimental 
manipulation.  Specifically, we found that: (1) FGF2 has a circadian pattern of 
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gene expression with a peak at 1600 h and a trough at 0800 h, (2) FGFR1 
expression oscillated with a peak at 2400 h and a trough at 1200 h, (3) FGF9 
gene expression showed no significant circadian variation over a 24-hour  light-
dark cycle, (4) the expression peak of FGF2 mRNA corresponded to the peak in 
circulating corticosterone in the same experimental animals, and (5) an acute 
microinjection of FGF2, administered between 0700 h and 0900 h increased the 
locomotor activity of adult rats during the dark-cycle (active period). These 
findings support the hypothesis that FGF2 and FGFR1 have differences in basal 
expression across a 24-hour light-dark cycle and that changes in FGF2 
availability have an effect on circadian locomotor activity. 
 
Our results indicated that the FGF2 ligand and its primary receptor in the 
hippocampus display basal circadian fluctuations in mRNA expression.  The 
peak of FGF2 expression, which occurs at the onset of the dark-cycle (active 
period), precedes the peak in expression of FGFR1.  This circadian mRNA 
expression pattern is also seen in another growth factor, brain-derived 
neurotrophic factor (BDNF), and its receptor, trkB (Bova, Micheli et al. 1998).  As 
it is explained for the BDNF/trkB rhythm, it is possible that FGF2 may play a role 
in regulating its own receptor.  Recent findings from our lab show that FGF2 
microinjections increased FGFR1 receptor mRNA in the hippocampus (Turner, 
Gula et al. 2008) supporting the hypothesis that FGF2 induction may regulate  
FGFR1 expression.  Also, it is possible that the induction of transcription of 
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FGFR1 may require intervening protein synthesis that results in a lag behind the 
peak expression of FGF2.  
 
Although FGF9 gene expression shows no circadian variation in expression, the 
ratio of FGF9 to FGF2 expression changes over a 24-hour light-dark cycle.  Our 
ecent studies have shown that microinjections of FGF9 result in behavioral 
changes in anxiety-like and depression-like behavior that are opposite that seen 
with exogenous administration of FGF2 (Inui, unpublished data; (Turner, Gula et 
al. 2008).  FGF9 microinjections also decreased the expression of FGFR1 
expression in the hippocampus (Inui, unpublished data).  The finding that FGF9 
is not altered over a 24-hour light-dark cycle, is important to understanding the 
interplay of FGF2 and FGF9 interaction.  The acute increase in depression-like 
behavior observed in the first-half of the light-cycle (0700 h to 1200 h), was not 
observed when FGF9 was administered during the second-half of the light-dark 
cycle (1300 h to 1700 h) (Inui, unpublished data).  This time-sensitive alteration 
in behavioral response may be mediated by an increase in FGF2 expression in 
the second-half of the light-cycle.  Alteration in the ratio of FGF2 and FGF9 may 
have behavioral consequences.  Upregulation of FGF9 expression, as seen in 
post-mortem tissue of individuals diagnosed with MDD, may lead to a disruption 
in the natural circadian variation of FGFR1.  Therefore, it is important to know 
that under basal conditions there is no circadian variation in FGF9 mRNA 
expression in the hippocampus however there is a circadian pattern to the 
FGF2/FGF9 expression ratio. 
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In this study, we found that the peak in FGF2 expression coincided with the peak 
in circulating plasma corticosterone in the same experimental animals.  Injections 
of corticosterone can lead to immediate (six hours post-injection) increases in 
FGF2 mRNA expression in many regions of the brain, including the hippocampus 
(Molteni, Fumagalli et al. 2001).  Also, early-life exposure to corticosterone 
causes long-term changes in FGF2 mRNA in the prefrontal cortex and 
hippocampus (Molteni, Fumagalli et al. 2001).  Conversely early-life injections of 
FGF2 caused long-term behavioral changes in adult rats (Turner, Capriles et al. 
2009).  While there is a strong link between the expression of FGF2 and 
corticosterone levels, we do not know if the changes in FGF2 expression result 
from changes in circulating corticosterone or if FGF2 is a mediator of the 
cortiscosterone response.  Additional experiments involving adrenalectomized 
animals given steady doses of corticosterone may help determine if the 
expression of FGF2 is indeed regulated by corticosterone. 
 
Interestingly, the peak expression levels of FGF2 corresponded to the peak in 
cell proliferation seen in adult rat hippocampus over a 24-h light-dark cycle. 
It has been shown that cell proliferation was highest in animals sacrificed at  
1700 h (the end of the light phase) and at its minimum in animals sacrificed at 
0500 h (the end of the dark phase) (Guzman-Marin, Suntsova et al. 2007).  Since 
FGF2 is known to support cell proliferation (Rai, Hattiangady et al. 2007) in the 
adult rat hippocampus, the synchrony in FGF2 mRNA expression supports the 
evidence that there is a distinct pattern of cell proliferation throughout the day. It 
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is thought that increases in cell proliferation may increase synaptic plasticity 
during an animals’ active period and allow for increased informational encoding 
about the animals’ environment (Lledo, Alonso et al. 2006).  In addition to 
supporting cell proliferation, FGF2 can also facilitate long term potentiation (LTP) 
in the hippocampus (Ishiyama, Saito et al. 1991; Abe, Ishiyama et al. 1992) .  An 
increase in FGF2 and cell proliferation at the onset of the dark-cycle (active 
period) may lead to increased synaptic plasticity and enhanced behavioral 
responsiveness to environment stimuli. 
 
In support of the hypothesis that increased FGF2 availability can correspond with 
alterations in behavior and normal circadian activity, we showed that an acute 
microinjection administered between 0700 h  and 0900 h increased locomotor 
activity during the dark-cycle (active period).  While it has been previously found 
that exercise can induce the expression of FGF2 in the hippocampus (Gomez-
Pinilla, Dao et al. 1997), this is the first time FGF2 has been shown to have an 
effect on locomotor activity during the dark-cycle (active period).  Continuous 
infusion of another growth factor, BDNF, increased locomotor activity in adult rats 
(Naert, Ixart et al. 2006).  Our lab has also shown that that rats bred for high-
response to novelty/low anxiety (HR) have higher FGF2 gene expression (Perez, 
Clinton et al. 2009) and also show an increase in dark-cycle (active period) 
activity compared to their low-response to novelty/ high-anxiety littermates (LR) 
(Clinton and Kerman, unpublished data).  It is possible that an increase in FGF2 
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expression is necessary for increased activity, increased exploration, and in turn 
a decrease in anxiety-like behavior. 
 
The changes in locomotor activity observed during the dark-cycle (active period) 
indicate that an increase in FGF2 can lead to alterations in circadian locomotor 
activity.  While we only found a several hour increase in locomotor activity after 
an acute injection, this finding is supportive of the hypothesis that chronic 
dysregulation could lead to changes in circadian locomotor activity.  It is possible 
that dysregulation of the FGF family could lead to long-lasting changes in sleep-
wake patterns seen in MDD.  Little is known about the mechanism underlying the 
disruptions of sleep patterns in individuals diagnosed with MDD.  However, 
fibroblast growth factor modulation may be a key mediator in circadian locomotor 
activity and maintenance of appropriate sleep-wake cycles.   
 
In conclusion, our results demonstrated that the expression of FGF2 and FGFR1 
in the adult rat hippocampus exhibited circadian variation under basal conditions.  
Furthermore, the circadian variation of FGF2 and FGFR1 may be directly related 
to physiological variations in stress hormones.  While FGF9 showed no circadian 
variation during a 24-hour light-dark cycle, the ratio of FGF2 to FGF9 gene 
expression does change over this period.  Thus, the dysregulation of FGF 
system may lead to disruption in endogenous circadian rhythms, such as 
locomotor activity and environmental responsivity.  These disruptions may be 




Figure 4-1: FGF2 mRNA circadian variation in the hippocampus. 
 
A. 







A) Representative FGF2 mRNA in situ hybridization images from expression 
peak (1600 h) and trough (0800 h).  B) FGF2 hippocampal gene expression 
fluctuated over a 24-hour light-dark cycle.  FGF2 expression showed peak 



















C) All four hippocampal subregions (CA1, CA2, CA3, and DG) contributed to the 







Figure 4-2: FGFR1 mRNA circadian variation in the hippocampus. 
 
A. 










A) Representative FGFR1 mRNA in situ hybridization images from expression 
peak (0400 h) and trough (1200 h). B) FGFR1 hippocampal gene expression 
fluctuated over a 24-hour light-dark cycle.  FGFR1 showed peak expression at 
2400 h and trough expression at 1200 h; *p < 0.05, **p < 0.01, (n=5-6 animals/ 
group). 
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C) All four hippocampal subregions (DG, CA1, CA2, CA3) contributed to the 
overall expression pattern of FGFR1 over a 24-hr light-dark cycle (5-6 
animals/group). 
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A) Representative FGF9 mRNA in situ hybridization images from expression at 
0400 h and 1600 h show that there is no significant fluctuation over a 24-hour 
light-dark cycle.  B) A schematic representation of the mRNA expression of FGF2 
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Lights off
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Circulating plasma corticosterone exhibited a distinct circadian rhythm with a 
peak at 1600 h and a trough at 0800 h; *p < 0.05, ***p < 0.001, (n=6-7 animals/ 





Figure 4-5: FGF2 microinjection increased locomotor activity during the 






A single microinjection of FGF2 (200ng, i.c.v.), administered between 0700 h and 
0900 h, increased locomotor activity during the dark-cycle (active period) 
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The current body of work encompasses a series of studies that supports the role 
of the FGF system in affective behavior and circadian activity.  We showed that 
exogenous microinjections of FGF9 can alter both anxiety-like and depression-
like behavior.  The effect of FGF9 administration was both dose-dependent and 
time-sensitive.  Acutely, FGF9 decreased anxiety-like activity and increased 
depression-like activity.  However, chronic FGF9 microinjections reversed the 
effect on anxiety-like behavior, from anxiolytic to anxiogenic, and further 
increased depression-like behavior. Furthermore, chronic FGF9 microinjections 
altered FGF system expression in the hippocampus.  Specifically, chronic FGF9 
injections decreased the expression of endogenous FGFR1 in the dentate gyrus 
of the hippocampus.   
 
In support of the hypothesis that FGF9 can be modulated by stressors 
responsible for changing affective behavior, FGF9 gene expression was 
upregulated by repeated social stress.  This stress paradigm concurrently altered 




avoidance behavior.  Gene expression changes in FGF9 were opposite those 
observed in previous studies that showed a decrease in FGF2 gene expression  
following social stress (Turner, Calvo et al. 2008).  The changes opposing 
changes in FGF2 and FGF9 further support the hypothesis that FGF2 and FGF9 
are physiological antagonists. 
 
Acutely, FGF2 increased anxiety-like behavior and decreased depression-like 
behavior.  Additionally, chronic FGF2 microinjections reversed the effect on 
anxiety, from anxiogenic to anxiolytic, while continuing to exhibit antidepressant-
like effects.  Chronic microinjections of FGF2 increased the expression of FGFR1 
in the dentate gyrus of the hippocampus.  Acute social defeat also 
downregulated FGF2 expression (Turner, Calvo et al. 2008).  The comparison of 
these results on affective behavior and expression regulation provides evidence 
that FGF2 and FGF9 may be physiological antagonists.  The mechanisms 
underlying the opposing effects on affective behavior and on gene expression 
regulation are still unknown.  However, these studies support the hypothesis that 
FGF9 mediates the negative aspects of affective behavior while FGF2 modulates 
positive effects on affective behavior.  Small-molecule inhibition of FGF9 may 
sbe an effective approach for novel antidepressant treatment.   
 
In addition to showing that FGF9 has a direct effect on behavior and can be 
altered by social stress, we also observed that FGF system expression in the 




expression of FGF2 showed peak expression at 1600 h and trough expression at 
0800 h.  The expression peak of FGF2 coincided with the expression peak of 
circulating plasma corticosterone levels.  This result may indicate that FGF2 is 
acting in concert with the circadian cycle of corticosterone in the hippocampus.  
Under basal conditions, increased expression of FGF2 during peak 
corticosterone secretion may be protective to hippocampal architecture, dendritic 
spine formation and arborization.  Additionally, increased FGF2 may allow for 
increased synaptic plasticity during the active/exploratory period.  Conversely in 
stressed animals, increased corticosterone secretion and decreased FGF2 
expression may lead to negative effects on hippocampal architecture and 
synaptic plasticity.  The expression of FGFR1 peak lagged behind that of FGF2, 
and it exhibited peak expression at 2400 h and trough expression at 1200 h.  
While FGF9 showed no distinct changes in gene expression over a 24-hour light-
dark cycle, the ratio of FGF2 to FGF9 over the 24-hour period is altered.  
Therefore, dysregulation of the FGF system may alter the endogenous 
physiological antagonism of FGF2 and FGF9 and in-turn circadian 
locomotion/environmental exploratory activity.    
 
An acute microinjection of FGF2, administered between 0700 h  and 0900 h, 
increased locomotor activity during the dark-cycle (active period).  Recent studies 
from our lab show that high-response to novelty/low anxiety rats (HR) have 
increased expression of FGF2 in the hippocampus.  Conversely, low-response to 




of FGF2.  Additionally, HR animals have increased activity during the dark-cycle 
(Clinton, unpublished data).  The FGF2 microinjection studies support the 
hypothesis that FGF system dysregulation can alter circadian locomotor activity 
and may play a role in environmental response underlying differences in anxiety.  
The series of circadian studies showed that FGF2 and FGFR1 gene expression 
have their own naturally occurring rhythms over a 24-hour period and that 
circadian locomotor activity can be disrupted by exogenous administration of 
FGF2. 
 
Taken together these results demonstrate that the FGF system exhibits highly 
complex regulatory mechanisms in response to stress, circadian cues, and 
exogenous growth factor manipulations.  The dysregulation of the FGF system 
may underlie changes in affective behavior and alter circadian locomotor activity.  
It is also possible that changes in circadian locomotor activity/exploratory activity 
may cause changes in affective behavior and mood. 
 
 
Role of FGF9 as a regulator of affective behavior 
 
 
We have observed behavioral responses after administration of intermediate 
doses of FGF9 (20ng or 200ng, i.c.v.).  Initially, FGF9 decreased anxiety-like 
behaviors and increased depression-like behavior.  However, higher doses of 
FGF9 did not alter affective behavior.  It is possible, that at higher doses FGF9 




members of the FGF family that has increased self-interaction (Plotnikov, 
Eliseenkova et al. 2001). However, the inverted-U shaped pharmacological 
response is also common when pharmacological agents are receptor agonists at 
lower concentrations and receptor anatagonists at higher concentrations 
(Calabrese 2003).  
 
Chronic microinjections of FGF9 reversed the anxiolytic effects observed with 
acute microinjection of FGF9.  The differential response of animals to the same 
treatment may rely on two separate mechanisms of FGF9 action.  The acute 
response may be a rapid neurotransmitter-like effect while the chronic response 
may involve istructural and plasticity related changes in the hippocampus.  The 
alteration of FGFR1 expression in the hippocampus following chronic 
administration with FGF9 supports the hypothesis that FGF9 may induce long-
term changes in the hippocampus. 
 
Acute treatment with selective serotonin reuptake inhibitors (SSRIs) increased 
anxiety-like behavior (Bagdy, Graf et al. 2001; Belzung, Le Guisquet et al. 2001; 
Burghardt, Bush et al. 2007). The increase in anxiety can be reversed by 
administration of a 5HT2C agonist while blockade of 5HT1A receptors 
exacerbates the anxiogenic response (Bagdy, Graf et al. 2001). The anxiety 
effects have been attributed to the initial decrease in serotonin release at the 
synaptic cleft.  This initial decrease in serotonin transmission could cause 




5HT1A autoreceptors and subsequent sensitization of post-synaptic receptors 
(File, Kenny et al. 2000).  It is likely that there is some cross-talk between the 
monoaminergic systems and FGFs.  This is supported by evidence that FGF2 is 
necessary for behavioral sensitization to drugs of abuse in cooperation with 
neurotransmitter interaction (Flores, Samaha et al. 2000).  Our lab has also 
shown that early-life FGF2 enhanced the acquisition of cocaine-self-
administration in adulthood (Turner, Capriles et al. 2009).  
 
While acute injection of FGF2 increased anxiety, acting similarly to 
antidepressants, FGF9 initially decreased anxiety.  While there is no mechanistic 
evidence, It is possible that FGF9 is directly mediating and increasing 
monoamine release at the synaptic cleft resulting in an acute decrease in 
anxiety.  In that respect, the use of methylenendioxyamphetamine (MDMA) as a 
model for acute action on the monoaminergic system may provide insight into the 
neurotransmitter-like properties of FGF9.  MDMA administration caused an initial 
increase in 5HT in the pre-synaptic cleft and acutely decreased anxiety-like 
behavior (Ho, Pawlak et al. 2004; Gudelsky and Yamamoto 2008).  
 
Prolonged administration of SSRIs results in decreased anxiety and decreased 
depression.  However, prolonged administration of MDMA led to decreased 
serotonergic tone and loss of serotonin transporters (SERT) (Battaglia, Brooks et 
al. 1988; Battaglia, Yeh et al. 1988).  The decrease in serotonergic tone was 




phase, levels of serotonin recovered to normal in 24 hours whereas long-term 
loss of serotonergic tone may begin within one week and persist up to one month 
(Schmidt 1987; Stone, Merchant et al. 1987).  Persistent MDMA administration 
can cause long-term increases in anxiety-like behavior (Morley, Gallate et al. 
2001; Fone, Beckett et al. 2002; Gurtman, Morley et al. 2002). In support of the 
hypothesis that a decrease in serotonergic tone is caused by MDMA, pre-
exposure to MDMA decreased the efficacy of antidepressants (Durkin, 
Prendergast et al. 2008).   
 
FGF2 is increased during antidepressant administration and may be acting in the 
restructuring of the serotonin system by decreasing post-synaptic monoamine 
release. FGF9 may acutely increase post-synaptic monoamine release in the 
hippocampus, thereby decreasing anxiety. Furthermore, long-term 
consequences of FGF9 may include an overall decrease in monoaminergic tone 
resulting in increased anxiety and depression.  A similar phenomenon has also 
been observed with amino acid neurotransmission via NMDA receptors.  While 
ketamine, a NMDA receptor antagonist, had acute antidepressant effects in vivo 
(Berman, Cappiello et al. 2000; Zarate, Singh et al. 2006), chronic NMDA 
receptor antagonism resulted in increased neurotoxicity, cognitive impairment, 
and even psychosis (Olney 1994; Newcomer, Farber et al. 1999; Young, 





We have examined the differential anxiety-like behavioral response to acute and 
chronic FGF9 administration.  It is possible that short-term decreases in anxiety 
may be attributed to the cross-talk between FGF and neurotransmitter systems.  
Furthermore, evidence supports that long-term neurotransmitter activity can lead 
to long-lasting cellular and behavioral changes.  While the FGF system may 
affect neurotransmitter activity, there is a growing body of evidence that growth 
factors have independent effects on affective behavior and structural changes in 
the hippocampus (Berton and Nestler 2006).   
 
 
Thoughts on the future of growth factors and antidepressant therapy 
 
 
A possible independent mechanism of growth factor action is encompassed by 
the emerging neurotrophic hypothesis of depression and antidepressant action 
(Duman 2004; Berton and Nestler 2006; Duman and Monteggia 2006). This 
hypothesis was originally based on findings that acute or chronic stress 
decreased expression of BDNF.  Conversely, antidepressants increased the 
expression of BDNF and reversed the effects of stress on hippocampal 
morphology (Chen, Dowlatshahi et al. 2001).  Stress caused a reduction in 
dendritic arborization that is reversed by antidepressants (Duman 2004).  
Additionally, exogenous administration of BDNF increased antidepressant-like 





The FGF system may also be involved in mediating changes in hippocampal 
morphology during stress.  FGF2 may have protective effects in the 
hippocampus as it is also increased with antidepressant treatment (Mallei, Shi et 
al. 2002), while FGF9 may exacerbate hippocampal atrophy during stress.   More 
work needs to be done to validate this hypothesis, particularly by looking at 
changes in hippocampal morphology after administration of growth factors 
independent of antidepressants. This hypothesis provides an explanation for the 
long-term independent effects of growth factors on hippocampal morphology and 
subsequently on affective behavior.  However, there is difficulty in targeting 
growth factor receptors as they are broadly expressed and lead to a complex 
cascade of signal activation.   BDNF also showed poor pharmacokinetic 
properties in clinical trials of degenerative disease (Pollack and Harper 2002; 
Pollack and Harper 2002).  Therefore, it may be wise to look towards other 
neurotrophic factors for therapeutic targeting. 
 
FGF9 presents a novel opportunity for the creation of a specific small-molecule 
antagonist.  An FGF9 antagonist may inhibit the negative effects of FGF9 on 
affective behavior and possibly on hippocampal morphology.  Additionally, 
identification of downstream signaling molecules increased by FGF9 may also 
provide later-stage targeting elements in the neurotrophic pathways.  To date, 
two downstream targets of neurotrophic factors have been investigated.  Direct 
inhibition of phosphodiesterase 4 (PE4), a molecule that is inhibited by 




clinical trials but is severely limited by side effects (Fleischhacker, Hinterhuber et 
al. 1992; Fujimaki, Morinobu et al. 2000; Jeon, Heo et al. 2005).  Another 
downstream target of neurotrophic factor inhibition, glycogen synthase 3 (GSK-
3), has shown antidepressant effects in animal models of depression but has not 
been tested in clinical trials (Gould 2006; Gould, Picchini et al. 2006).  Further 
research into the downstream molecules affected by FGF9 upregulation may 
lead to increased targets for small-molecule inhibition with decreased side 
effects. 
 
It is possible that FGF9 has direct action on neurotransmitter systems and 
independent effects on hippocampal morphology. However, FGF9 may be 
mediating both its acute neurotransmitter-like and chronic behavioral impairment 
via direct antagonism of FGF2. 
 
 
Role of FGF9 as a physiological antagonist of FGF2 
 
 
As FGF9 consistently altered affective behavior in a manner opposite that seen 
after administration of FGF2, it is possible that FGF9 is acting as a physiological 
antagonist to FGF2.  It is unlikely that FGF9 is binding to FGFR1, due to the 
steric hindrance that results in decreased activation of this receptor by FGF9 
(Reuss and von Bohlen und Halbach 2003).  However, chronic microinjections of 




hippocampus.  This in turn would reduce the effects of FGF2-mediated FGFR1 
activation in the dentate gyrus.   
 
While the mechanism for FGFR1 reduction remains unknown, FGF9 decreased 
the differentiation of GFAP-positive astrocytes in vitro (Lum, Turbic et al. 2009).  
Recently, our lab has shown that administration of FGF2 increased the 
production of GFAP-positive astrocytes (Perez, Clinton et al. 2009).  It is possible 
that the opposing effects of FGF2 and FGF9 in astrocyte formation are structural 
changes that alter hippocampal function.  Loss of glial cells has also been noted 
in animal models of depression and in depressed patients (Cotter, Mackay et al. 
2001; Cotter, Pariante et al. 2001; Sheline 2003; Rajkowska and Miguel-Hidalgo 
2007).  Additionally, ablation of glia in the prefrontal cortex can lead to 
depression-like behavior (Banasr and Duman 2008).   
 
Since most of the evidence of FGF2 and FGF9 effects on glial cells is focused on 
astrocytic mediation, it is important to note that astrocytes are the primary site of 
synthesis for FGF2.  FGF9-mediated decreases in astrocytic differentiation would 
lead to an overall decrease in FGF2.  This may be another mechanism for the 
differential behavioral responses seen with these ligands.  Modulation of 
astrocytic populations may be an underlying mechanism for fibroblast growth 





Astrocytes can modify synaptic transmission and plasticity through modulation of 
glutamatergic signaling (Verkhratsky, Orkand et al. 1998).  Through glutamate 
uptake astrocytes can modulate the duration of the synaptic current and can 
protect from potential excitotoxic damage.  An FGF9-mediated decrease in 
astrocytes (Lum, Turbic et al. 2009) could result in increased neurotoxicity.  
Astrocytes are also involved in the development and remodeling of synaptic 
functions and the promotion of synapse formation (Pfrieger 2002).  Furthermore, 
astrocytes are responsible for the conversion of l-serine to d-serine (Wolosker, 
Blackshaw et al. 1999), and d-serine is necessary for the coactivation of NMDA 
receptors (Johnson and Ascher 1987).  Regulation of the amount of d-serine may 
in-turn affect NMDA receptor activation.   
 
As described above, acute administration of NMDA receptor antagonist, 
ketamine, has antidepressant-like effects (Berman, Cappiello et al. 2000; Zarate, 
Singh et al. 2006).  However, chronic antagonism may lead to neurotoxicity 
(Newcomer, Farber et al. 1999).  Chronic suppression of astrocytic 
differentiation, by increased exogenous FGF9 or endogenous FGF9 expression, 
could lead to long-term decreases in synaptic plasticity and subsequently 
negative behavioral consequences.   Conversely, FGF2- induced increases in 
astrocytic proliferation (Perez, Clinton et al. 2009) could mediate the 






Potential for FGF9 as a novel antidepressant target 
 
 
While the potential peptide antagonist to the “low-affinity loop” of FGF9 may not 
have altered depression-like behavior in the experiment described in chapter two, 
FGF9 still has potential for inhibition.  It is possible that the potential peptide 
antagonist may require higher concentrations for efficacy or may have more 
robust activity on different molecular or behavioral endpoints.  However, further in 
vitro assays are necessary for the validation of a peptide antagonist or possibly a 
small molecule inhibitor for FGF9.  Alternatively, sequence-specific knockdown 
by RNA interference in vivo may provide a biologically relevant approach to 
ligand regulation (Pardridge 2007).   Additionally, antibody neutralization is 
another alternative to determine the effects of FGF9 activity blockade (Tao, Black 
et al. 1997).  While these methods of inhibition will help validate FGF9 as a target 
for mood disorders, they would not be ideal therapeutics.   
 
To date, BDNF and other growth factors have shown poor pharmacokinetic 
properties and low efficacy in degenerative disease patients (Pollack and Harper 
2002).  Additionally, development of small-molecule agonists of neurotrophic 
receptors has been unsuccessful.  FGF2, BDNF, and other growth factors 
require increased expression or increased receptor activation for positive effects 
on depression-like and anxiety-like behavior.  Conversely, FGF9 presents a 
novel target for specific inhibition to decrease its negative effects on affective 
behavior.  This decrease in FGF9 activity could be achieved by blocking ligand-




the receptor site with a non-activating molecule could prevent FGF receptor 
signaling.  However blocking the receptor would block all ligand activation and 
not just that of FGF9. While further research is necessary to validate effective 
peptide antagonists or small-molecule inhibitors, FGF9 provides a unique 
neurotrophic target for the treatment of mood disorders.  Decreased FGF9 
activity may lead to an improvement in depression symptoms and decreased 
anxiety. 
 
Ultimately, complete inhibition of FGF9 activity may not be ideal.  FGF9 may act 
as a physiological antagonist to FGF2 for a regulatory purpose.  While a brief 
relief from the physiological antagonism may boost FGF2 activity, increased 
synaptic plasticity and antidepressant properties, long-term increases in FGF2 
expression may also be detrimental.  FGF9 inhibition may be more of a selective 
rather than chronic treatment.  For example, electroconvulsive therapy increases 
growth factor expression and improves mood and is used as a “jump-start” in 
patients that are unresponsive to standard antidepressant medication.   
 
 
FGF system as a mediator of circadian activity 
 
 
While initial studies involving the timing of FGF9 administration led us to 
investigate the basal circadian expression of the FGF2 system, this series of 
studies supports the hypothesis that FGF2 dysregulation may alter basal 




that the administration of FGF9 acutely decreased escape behavior when 
administered in the first-half of the light-cycle.  However, this result was not 
replicated when animals were injected and tested in the second-half of the light-
cycle.  Endogenous circadian-mediated decreases in overall escape activity may 
have masked the decrease in escape activity caused by FGF9 microinjections 
(Kelliher, Connor et al. 2000).  However, it is also possible that FGF9 activity was 
diminished by the increased expression of FGF2 that occurs during the second-
half of the light-cycle.  The ratio of FGF2 to FGF9 at a given time-point may 
determine the effect of the ligands on synaptic plasticity and on affective 
behavior.   
 
Importantly, FGF2 gene expression and circulating plasma corticosterone were 
increased at the onset of the active period.  Since exogenous corticosterone and 
acute stress can both increase FGF2 expression (Molteni, Fumagalli et al. 2001), 
it is possible that FGF2 modulating the circadian effects of corticosterone in the 
hippocampus.  FGF2 expression may be elevated while corticosterone secretion 
is in order to protect against architectural damage caused by elevated 
glucorticoids.  This simultanous increase of FGF2 expression and corticosterone 
may be one mechanism for increasing environmental responsivity and synaptic 
plasticity.  Further investigation into the effect of circadian corticosterone 
regulation of FGF2 expression is necessary to determine the involvement of 




of the FGF system in circadian locomotor activity may be another mechanism by 
which FGF dysregulation can underlie the pathophysiology of depression. 
In support of this dissertation recent studies from our lab and others show 
support the role of the FGF system in affective behavior (Molteni, Fumagalli et al. 
2001; Molteni, Lipska et al. 2001; Fumagalli, Bedogni et al. 2005; Riva, Molteni et 
al. 2005; Akil, Evans et al. 2008; Turner, Calvo et al. 2008; Turner, Gula et al. 
2008; Perez, Clinton et al. 2009).  Additionally recent work has implicated the 
FGF family in drug abuse behavior (Fumagalli, Pasquale et al. 2006; Fumagalli, 
Di Pasquale et al. 2008; Turner, Flagel et al. 2008; Fumagalli, Franchi et al. 
2009; Turner, Capriles et al. 2009) which is important as depression is a 
behavioral sequelae of addiction (Shaffer, LaPlante et al. 2004).  The above 
discussion revisits the findings supporting the novel role for FGF9 in affective 
behavior as well as the involvement of the FGF system in the amplitude of 
circadian locomotor activity.  The present studies support the hypothesis that 
FGF9 may mediate the long-term negative aspects of depression.  Additionally, 
the dysregulation in FGF system expression may underlie pathophysiological 






Microinjections of FGF9 into the lateral ventricle of the brain did not allow us to 




below, central microinjections may alter multiple brain regions associated with 
behavior.  Therefore the observed results are a sum of the effect observed over 
multiple brains region.  As the FGF system is expressed diffusely throughout 
many brain regions, it is difficult to quantify gene expression in regions other than 
the hippocampus, such as the nucleus accumbens, ventral tegmental area, and 
amygdala.  However, further assessment of the FGF system in these regions is 
necessary to fully understand the dysregulation of the FGF system in mood 
disorders. Site-specific injections into these regions may elucidate the action of 
FGF9 in regards to affective behavior. 
 
Additionally, the above studies focused on the dysregulation of gene expression 
through mRNA analysis.  However, we showed no evidence of protein-level 
changes in the hippocampus.  It is possible that alterations in mRNA transcription 
do not necessarily correlate to changes in protein expression.  As therapeutics 
for FGF9 antagonism would focus on the protein-level inhibition, it is important to 
characterize both changes and protein and post-translational modifications of 
FGF9. 
 
As FGF2 has been shown to increase astrocytes, increase cell proliferation, and 
support neurogenesis in adult rats, these mechanisms were not explored in the 
above studies.  As FGF9 has behavioral effects opposite those seen with FGF2 
administration, we would hypothesize that FGF9 would decrease astrocytes, 




identify the mechanism of FGF9, it is often difficult to observe differences in basal 
changes of adult cell proliferation.  As adult rodents have a fairly low basal level 
of neurogenesis and cell proliferation, observing a decrease in these 
hippocampal changes will be a challenge. 
 
While our circadian studies focused on basal gene expression fluctuations of 
FGF system in the hippocampus, we did not identify disruptions in these gene 
expression rhythms following a stressor.  We would hypothesize that a stressor, 
such as repeated social stress, would disrupt the regulation of FGF system 
expression in the hippocampus and subsequent locomotor behavior.  It may also 
be informative to test locomotor response to novelty after FGF2 microinjection 
and during the dark-period in order to determine if exogenous FGF2 increases an 
animals’ environmental responsivity.  We also did not show if the fluctuations of 
FGF2 and FGFR1 are the result of circadian corticosterone regulation.  Further 
studies, using adrenalectomized rats could determine if the changes in FGF 
system expression are corticosterone-dependent.  Additionally adrenalectomized 
rats could be administered steady corticosterone treatment to look at the effect 
on FGF system expression when there is present but not fluctuating 
corticosterone secretion. 
 
We have evidence that rats bred for high response to novelty (HR) have higher 
FGF2 gene expression in the hippocampus (Perez, Clinton et al. 2009) and have 




However, we did not show that animals bred for low response to novelty have an 
increase in FGF9 gene expression in the hippocampus.  This information would 
support our hypothesis that the expression of FGF2 and FGF9, as well as the 
ratio of expression, has an effect on environmental responsivity.  Additionally, we 
also have evidence that neonatal FGF2 administration can increase cocaine self-
administration in rats, but we have not tested this hypothesis in animals 






There are incremental steps for the further characterization of FGF9 as an anti-
depressant target.  Additionally, there are larger experimental leaps that can be 
made to develop novel therapeutics for peptide antagonism or small-molecule 
inhibition of FGF9.  While the FGF system is a good target for emerging 
therapeutic studies, we must continue to develop a greater understanding of the 
pathophysiology of depression by increased mechanistic probing.  Additionally, 
research characterizing the post-translational modifications caused by 
environmental influence may provide further insight into the underpinnings of the 
interaction between environment and depression. Finally, analysis of individual 
variances in response to antidepressant treatment may also allow for more 





The behavioral characterization of FGF9 inducible knockout mice may further 
validate the role of FGF9 in affective behavior.  Additionally, current techniques 
allow for selective knockout of your inducible gene of interest in specific brain 
regions using inducible RNA interference (Hitz, Wurst et al. 2007).  This selective 
FGF9 knockout could further elucidate the role of the hippocampal FGF9 and 
FGF2 in affective behavior.  As exogenous microinjection of FGF9 was directed 
into the lateral ventricle, FGF9 may have been mediating effects through other 
brain regions important to mood regulation.  Recent studies have shown that 
different brain regions can have opposing influences on depression-like behavior.   
 
Specifically, addition of exogenous BDNF to the hippocampus or posterior mid-
brain nuclei attenuated depression-related phenotypes (Shirayama, Chen et al. 
2002).  However, intra-ventral tegmental area (VTA) infusions of BDNF resulted 
in increased depression-like effects (Eisch, Bolanos et al. 2003).  As depression 
is marked by anhedonia, or lack of reward, it is suggested the dopaminergic cells 
in the VTA and their terminal fields in the nucleus accumbens (NAc) mediate the 
reinforcing effects of drugs of abuse, food, and sex (Koob 1998; Bassareo and Di 
Chiara 1999; Everitt, Parkinson et al. 1999). Dyresgulation of the reward 
pathways may also contribute to the pathopysiology of depression (Di Chiara, 
Tanda et al. 1999; Gambarana, Tolu et al. 2001; Nestler, Barrot et al. 2002). 
Additionally, other molecules implicated in depression, CREB and S-adenosyl-L-
methionine, also have differential effects in the hippocampus compared to the 




Olivier et al. 2002).  It is important to fully understand the overall effects of FGF9 
administration to multiple brain regions to avoid unwanted side-effects on mood. 
 
While a structural analysis-based approach to peptide design, we did not observe 
any changes in depression-like behavior after administration of the LAL peptide.  
While in vivo experiments present the best approximation of the translational 
value of a peptide antagonist, it is difficult to optimize in this way.  As 
sophisticated high-throughput cell based assays are available for in vitro 
assessment, advanced tools exist for rational screening of potential therapeutic 
compounds (Uttamchandani and Yao 2008; An and Tolliday 2009).  However, 
the assay would have to assess a downstream molecule of FGF9 activation and 
given the complexity of the signaling system this approach will be challenging. 
 
Recent investigations of epigenetic mechanisms underlying the pathophysiology 
of depression attempt to explain high discordance rates between monozygotic 
twins, the differences among inbred rats, the chronic relapse nature of the illness, 
and the increased prevalence of depression in females (Mill and Petronis 2007).  
Post-translational modification may be a mechanism by which environmental 
experiences can alter gene expression in the absence of DNA sequence 
modification in the brain.  Epigenetic changes have been implicated in a number 
of psychiatric disorders (Tsankova, Renthal et al. 2007); however, depression 
research has focused on two main chromatin-modifying processes. Histone 




may be a key mechanism for antidepressant action (Tsankova, Kumar et al. 
2004) .  Increased histone acetylation of the BDNF promoter is required for the 
antidepressant actions of imipramine to reverse the negative behavioral effects of 
social defeat (Tsankova, Kumar et al. 2004; Tsankova, Berton et al. 2006).  
Additionally, histone deacetylase (HDAC) inhibition showed increased 
antidepressant-like activity in the social defeat paradigm (Tsankova, Berton et al. 
2006; Schroeder, Lin et al. 2007).   
 
While histone acetylation can be altered by experience and modulate gene 
expression, DNA methylation can also be modified by environmental factors 
(Jaenisch and Bird 2003).  The methylation of the glucocorticoid receptor (GR) 
promoter was enhanced when mothers provided inadequate maternal care 
characterized by licking and grooming behavior (Weaver, Cervoni et al. 2004).  
This alteration resulted in decreased binding of transcriptional enhancers that 
regulate GR gene expression. Early-life molecular imprinting increased anxiety-
like behaviors and persisted into adulthood (Weaver, Cervoni et al. 2004). The 
long-lasting effects of epigenetic modifications may provide an explanation for 
why childhood trauma increases the risk for mood disorders in adulthood (Heim 
and Nemeroff 2001; McGowan, Sasaki et al. 2009). Modification of histones can 
facilitate or inhibit the access of associated proteins necessary for regulation of 
gene expression.  Further investigation of epigenetic modification in response to 
environmental factors may lead to an increased understanding of the interaction 




While epigenetic modifications may undermine individual genetic polymorphisms 
by modifying genetic promoters (Mill and Petronis 2007), there is still reported 
value in the assessment of individual differences.  As we hope to eventually 
realize the potential of pharmacogenomics and pharmacokinetics, further 
research into individual responses to treatment and genetic characterizations is 
necessary.  This genetic information may provide information for effective 
antidepressant treatments and minimized side effects.   
 
To date, most antidepressant pharmacogenomic studies have focused on 
candidate genes in the monoaminergic pathways.  The strongest findings of 
individual differences in depression, from clinical trials with more than two 
thousand patients, are as follows: (1) FK506-binding protein (FKBP5), a 
glucocorticoid-receptor-regulating co-chaperone, polymorphism is associated 
with a beneficial antidepressant response (Binder, Salyakina et al. 2004; 
Lekman, Laje et al. 2008),  (2) 5-hydroxytryotamine receptor 2A (HTR2A), a 
serotonin receptor that mediates the effects of atypical antipsychotics, 
polymorphism is associated with outcome of antidepressant treatments and 
antidepressant side effects (Sato, Yoshida et al. 2002; McMahon, Buervenich et 
al. 2006; Suzuki, Sawamura et al. 2006), and (3) kainic- acid-type glutamate 
receptor KA1 (GRIK4), a receptor responsible for fast-acting gluatamatergic 
neurotransmission may be associated with treatment-resistant dependence 
(Paddock, Laje et al. 2007).  Further analysis of genetic polymorphisms from 




both treatment selection and potential novel genetic targets.  Understanding the 
interaction between genetic predisposition and environmental factors is of 
paramount importance for rational drug design and personalized treatment of 
mood disorders. 
 
In conclusion this dissertation provides support for the hypothesis that FGF9 has 
negative effects on anxiety-like and depression-like behavior.  In addition, FGF 
system expression shows daily variation in the hippocampus and changes in 
FGF2 can alter daily locomotor activity.  Dysregulation of the FGF system may 






Specifically, we observed that: (1) early-life and peripheral administration of 
FGF9 did not alter adult behavior, (2) acute microinjection of FGF9 resulted in 
anxiolytic and depressionogenic behavior in adult rats, (3) chronic microinjections 
of FGF9 were anxiogenic and depressionogenic in adult rats, (4) chronic 
administration of FGF9 decreased the dentate gyrus gene expression of the 
FGFR1 receptor, (5) repeated social stress increased social avoidance and the 
hippocampal gene expression of FGF9, (6) both FGF2 and FGFR1 gene 
expression exhibited hippocampal variation over a 24-hour light-dark cycle, (7) 
an acute microinjection of FGF2 can alter the amplitude of circadian locomotor 




behavior and was altered by increased stress.  Additionally, this is the first time 
that the daily fluctuation of the FGF system over a 24-hour light-dark cycle and its 
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